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ABSTRACT 
INVESTIGATION INTO SELECT ISOQUINOLINES 
AS A PUTATIVE CAUSAL AGENT OF ETHANOL ADDICTION IN MAMMALS 
by Jacob Christopher Strawbridge 
May 2009 
Alcohol is the most abused drug in America today. The neurological root of the 
problem is still a much debated subject and many differing views exist on the nature of 
alcoholism, be it a social dysfunction or a neurochemical imbalance. Some researchers 
have proposed that a skewed metabolism of dopamine that results in the formation of 
tetrahydroisoquinoline (THIQ) alkaloids plays a major role in the neurochemical 
acquisition and maintenance of alcohol addiction. In an effort to better understand the 
relationship of THIQ's to alcohol addiction, a series of experiments have been conducted. 
The chiral separation via high pressure liquid chromatography (HPLC) of various 
salsolinol (SAL) and salsolinol-derived compounds using a macrocyclic substituted 
sugar, sulfated P-cyclodextrin, as a chiral mobile phase additive was investigated. These 
HPLC separations yield data on a cheap and effective method for resolving enantiomers 
of simple catecholamines. The second set of experiments involved measuring the ethanol 
intake of rats given intracerebro ventricular (ICV) injections of racemic 
tetrahydropapaveroline (THP) and R-(+)-THP. A similar experiment was conducted with 
tetrahydroberbine (THB). Finally, rats were administered ethanol solutions via gavage 
u 
and the local cerebrospinal fluid (CSF) in the lateral ventricle of the rats' brains was 
sampled via microdialysis. These dialysate solutions were assayed for THP concentration 
using high pressure liquid chromatography with electrochemical detection (HPLC-ECD). 
The results of our experiments indicate that THP is formed in vivo in the rat brain and 
THP levels increase in response to ethanol ingestion. This finding appears to support the 
hypothesis that THP plays an important role in the etiology or symptoms of alcoholism in 
humans. 
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CHAPTER I 
INTRODUCTION AND BACKGROUND 
Ethanol and Alcoholism 
Throughout history, ethanol has played an important part in human society. It 
has inspired uncounted artists, musicians, and poets. However, one cannot speak of 
ethanol without coming to grips with alcoholism. Alcoholism has been defined by 
Koob, a prominent addiction researcher, as a complex behavioral disorder 
characterized by excessive consumption of ethanol, the development of tolerance and 
dependence, and impairment in social and occupational functioning [1]. Alcoholism 
is a serious health concern in America, as alcohol is the most widely used 
psychoactive drug [2] and is the third leading cause of preventable death in America 
[3]. A relative comparison of the alcohol-related healthcare costs versus the 
corresponding health care costs for all other drugs of abuse can be seen in Figure 1 
[4]-
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Figure 1: Comparison of Estimates From the Major Cost-of-Illness Studies for 
Alcohol and Drug Abuse, Adjusted for Inflation and Population Growth [4] 
In January 1987, the National Institute of Alcohol Abuse and Alcoholism 
(NIAAA) stated that two-thirds of the American population drank ethanol. However, ten 
percent of those who drank accounted for one half of all the alcohol consumed [5]. In 
1994, it was estimated that nearly eight million Americans were alcoholics [6]. Clearly, 
the etiology of alcoholism merits further study. 
A better understanding of the phenomena associated with craving of ethanol and 
the reward mechanisms involved could lead to more efficient treatments for alcoholics. 
Due to the complexity of alcohol addiction in humans, a problem that has psychological, 
genetic, sociological, and ethical components, researchers rely on the use of animal 
models, genetic profiling of family histories, and anecdotal accounts to assess the 
neurochemistry of ethanol addiction. 
The metabolism of ethanol in the liver and brain of mammals is well established 
[7, 8]. As shown in Figure 2, ethanol is converted to acetaldehyde by alcohol 
dehydrogenase found in cytosol, the liquid component of the cytoplasm, and the cofactor 
nicotinamide adenine dinucleotide (NAD+). Acetaldehyde is then oxidized by an NAD+ -
dependent aldehyde dehydrogenase found in mitochondria and NAD+ to form the acetate 
ion. This acetate product is then eliminated from the body. 
CH3CHtOH Ethanol 
Alcohol dehydrogenase 
(Cytosol) 
OHl^ C - H 
II Acetaldehyde 
Acetaldehyde 
dehydrogenase 
(Mitochondria) 
CH3C - O" 
li 
0 Acetate 
Figure 2: The Metabolism of Ethanol 
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Ethanol exerts its intoxicating effects on the central nervous system (CNS) by 
shifting the normal processes of information conduction and transmission in an indirect 
manner. A nerve cell must maintain a certain concentration of K+, CI", and Na+ in the 
extracellular fluid in order to generate action potentials and allow Ca+2 to release 
neurotransmitters. When an action potential reaches the terminus of the axon, ions 
enter the presynaptic terminal through voltage-gated ion channels specific for Ca+2 and 
signal the release of the stored dopamine into the synaptic cleft. 
Insights into the mechanisms by which ethanol affects CNS activity have been 
derived primarily from neurochemical assessments of ethanol's actions. Ethanol is known 
to inhibit sodium and potassium ion channels in the brain [9-12]. Ethanol has also been 
shown to increase calcium ion binding in the brains of rats and mice [13], resulting in a 
decrease in free calcium ions in select brain areas [14]. 
While these discoveries may help explain the effects of ethanol on nerve signal 
conductance, the complexity of the neural environment of even experimental animals has 
produced a controversy in the neuroscience community over the exact mechanism by 
which ethanol dependence operates. The current controversy revolves around the causal 
agents of dependence and whether changes in the dopaminergic, the endogenous opioid 
systems, or other circuits play the most important role in the etiology of alcoholism. 
5 
Dopamine as a Neurotransmitter 
Dopamine (DA) is one of the major neurotransmitters in the CNS. Figure 3 shows 
five of the prominent neurotransmitters. Dopamine, also called hydroxytyramine, is a 
monoamine intermediate formed from dihydroxyphenylalanine (DOPA) during the 
metabolism of the amino acid tyrosine [15]. Figure 4 demonstrates the synthesis of 
dopamine in the CNS. 
Figure 3: Five Major Simple Neurotransmitters 
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Figure 4: Dopamine Synthesis In Vivo From Tyrosine 
Dopamine is commonplace in the medial forebrain bundle and important in the 
substantia nigra, basal ganglia, and corpus striatum of the brain [16-19]. Figure 5 shows a 
variety of dopamine pathways located in the human brain. Dopamine can be both 
excitatory and inhibitory, depending on the postsynaptic receptor. It has been implicated 
in several functions, including locomotion, learning, attention, temperature regulation 
[15], and as a reinforcing agent for drugs of abuse via the nucleus accumbens and the 
mesolimbic reward pathway [1, 20-27]. 
frontal lobe 
basal ganglia 
Figure 5: An Overview of Dopamine Pathways in the Human Brain 
Dopamine, once synthesized, is stored in vesicles in the presynaptic neuron's 
terminal button. Ca ions enter the presynaptic axon and signal the release of dopamine 
into the synaptic cleft. This released dopamine then binds with postsynaptic receptors and 
generates a signal, either excitatory or inhibitory, in the postsynaptic neuron. This process 
is then repeated in the next series of dopaminergic neurons. A schematic of a normal 
dopaminergic synapse appears as Figure 6. 
8 
Figure 6: A Diagram of a Dopaminergic Synapse 
The metabolism of dopamine is, in part, a simple oxidation. Dopamine is oxidized 
by monoamine oxidase (MAO) to 3,4-dihydroxyphenylacetaldehyde (dopaldehyde). 
Dopaldehyde is oxidized by aldehyde dehydrogenase to form 3,4-dihydroxyphenylacetic 
acid (DOPAC). Figure 7 shows the known dopamine metabolism in mammals [28-31]. 
dopamine dopaldehyde DOPAC 
COOH 
Figure 7: Dopamine Metabolism 
Catecholamine Theory of Alcohol Addiction 
Two slightly different mechanisms for the development of alcoholism were 
suggested independently by separate groups some thirty years ago. The first involved the 
formation of tetrahydroisoquinoline (THIQ) alkaloids from the condensation of dopamine 
or DOPA with acetaldehyde, the first metabolite of ethanol [32]. This condensation 
reaction produced a 1-methyl-THIQ, salsolinol (SAL), and its carboxylated derivatives, 
the D and L isomers of 3-carboxysalsolinol (D-3-CSAL and L-3-CSAL). Another 
condensation of dopamine with pyruvic acid produces the 1-carboxysalsolinol (1-CSAL) 
derivative of SAL. Figure 8 shows the relevant reactions involved in these condensations. 
This theory was supported by the discovery that SAL could be formed in vitro by 
perfusing bovine adrenal gland homogenates with acetaldehyde solutions [32]. Further 
studies confirmed that SAL was formed in vivo in rat [33, 34] and in man [35, 36]. More 
recently, it was shown that the condensation of dopamine and acetaldehyde to form SAL 
is enzymatically driven, hence forming a majority of the R-(+)-isomer of SAL [37, 38]. 
Other studies have shown that intracerebroventricular (ICV) perfusion of SAL can elicit a 
drinking response from alcohol avoiding animals [39, 40]. Recently, SAL has been the 
10 
object of study because of the neurotoxicity of one of its metabolites that may be a 
contributing factor in the development of Parkinson's disease [41-43]. 
H O ^ 
H O " 
HCU 
H O " 
HO N 
H O " 
HO. 
HO' 
if^V 
Dopamine 
TPT" 
^ ^ 
L-DOPA 
XX 
D-DOPA 
N - " ^ V " " XT 
^ 
1 , + p u p u n » 
acetaldehyde 
H 
\ i - C O O H 
NH2 + CH3CHO 
^COOH 
XC + CH3CHO 
\ 
,1, + CH3COCOOH 
pyruvic acid 
H O . 
HO 
r"^V^i 
H3C" H 
R-(+)-SAL 
H O \ / 
^~ 1 I 
HO 
+ 
^ 
^ 
L-3-CSAL 
H 0 \ / 
HO 
^ > 
^ 
D-3-CSAL 
H O ^ 
' H O " 
f* 
H O . ^ ^ IT 
H O " ^ ^ " ^ ? 
'H* 
S-(-)-SAL 
H 
^ \ i - C O O H 
k ^ N H 
H VCH3 
^ COOH 
^ . N H 
H CH3 
H O O C ^ c H , 
D.L-1-CSAL 
^ N H 
CH3 
Figure 8: The Formation of SAL and CSAL 
Another group of researchers [31] proposed the second major catecholamine 
theory of alcoholism at virtually the same time. This theory held that the presence of 
acetaldehyde could inhibit the conversion of dopaldehyde to DOPAC, as acetaldehyde 
has a high affinity for aldehyde dehydrogenase also [31]. Alcohol, by way of its primary 
metabolite acetaldehyde, facilitates the formation of tetrahydropapaveroline (THP) by 
11 
competitively inhibiting aldehyde dehydrogenase in vitro. Under circumstances of 
substantial alcohol ingestion in vivo, the limited ability of the brain to oxidize aldehydes 
could contribute to the formation of THP [28-31]. This inhibition would lead to high 
levels of dopaldehyde accumulating in the brain and could lead to the condensation of 
dopamine with dopaldehyde to form 1-benzyl-THIQ, tetrahydropapaveroline [31]. 
THIQ's were originally isolated in plants under strongly acidic conditions by the 
Pictet-Spengler condensation reaction [44]. It was subsequently demonstrated that THIQ 
alkaloids can be formed under physiologic conditions of pH and temperature from the 
condensation of aldehydes, such as acetaldehyde, with catecholamines, such as dopamine 
and its N-methyl congener, epinephrine [45]. 
Davis and Walsh found that THP could be formed in vitro by incubating rat brain 
stem homogenates rich in dopamine, with acetaldehyde and NADH, which is used as a 
cofactor to retard the further metabolism of acetaldehyde [31]. The presence of THP in 
rat brain was verified by infrared spectroscopy, gas chromatography, and thin-layer 
chromatography [29-31]. Other researchers used thin-layer chromatography to 
demonstrate the formation of THIQ alkaloids in vitro by perfusing bovine adrenal gland 
with dilute acetaldehyde solutions [32]. This hypothesis was also supported by reports 
that THP occurred in vivo in the brains of rats [33, 34, 46] and humans [35, 36, 47, 48]. 
Thus, buildup of THP following alcohol intake, might have pharmacological effects 
relevant to the etiology of alcoholism. 
Although the majority of ethanol is metabolized by alcohol dehydrogenase, 
catalase, a ubiquitous enzyme found in large amounts in peroxisomes, can oxidize 
ethanol as a co-substrate with hydrogen peroxide to yield water and acetaldehyde [49]. 
12 
Hydrogen peroxide is produced in brain tissue when monoamine oxidase (MAO) 
oxidizes biogenic amines. Thus, catalase can use hydrogen peroxide to metabolize 
ethanol to acetaldehyde in the brain, resulting in a large concentration of acetaldehyde 
localized at dopaminergic neurons [8]. 
Alternatively, acetaldehyde inhibits the degradation of dopamine to 
dihydroxyphenylacetic acid. This increases the availability of aldehydes for participation 
in a Pictet-Spengler condensation with intact dopamine. If aldehyde dehydrogenase is 
occupied with the metabolism of acetaldehyde, the biogenic aldehyde could condense 
with its parent amine, resulting in THP formation. In fact, a recent report has shown that 
pharmacological inhibition of MAO-A reduced the volitional consumption of ethanol, 
perhaps by preventing the formation of both biogenic aldehydes and acetaldehyde and 
preventing the formation of the alkaloidal products [8]. 
Since THP is a precursor in the synthesis of morphine and other alkaloids in 
Papaver somniferum, the opium poppy, it was suggested that the formation of THP might 
contribute to the development of addiction by acting as a false transmitter or opiate 
agonist [29, 31, 50]. Additionally, THP might be further metabolized to form the opiates 
themselves. Figure 9 shows this proposed "skewed" metabolism of dopamine resulting in 
the formation of THP and hypothesized pathways (appearing as a dashed reaction arrow) 
by which THP could be converted to opiate alkaloids and tetrahydroxyberberine 
compounds [31]. Recently, S-(-)-THP was documented as being present in human brain 
tissue at concentrations of 0.12 to 0.22 pmol/g [51]. Morphine has also been reported to 
be endogenous to the CNS [52]. 
13 
MAO 
N H . 
HO-
HO 
"CHO „ H ° -
//* 
HO-
'COOH 
DOPAMINE 
HO 
HO 
HO 
HO 
3 , 4 - DIHYDROXYPHENYL- 3, 4 DIHYDROXYPHENYL-
ACETALDEHYDE A C E T I C ACID 
NH 
T E T R A H Y D R O P A P A V E R O L I N E 
(NOR L A U D A N O S O U N E ) 
HO-
HO-^^J 
NORMORPHINE, R = H 
MORPHINE , R = CHs 
NH 
Figure 9: Proposed Dopamine Metabolism Resulting in the Formation of 
THP and Possibly Opiate Alkaloids [31] 
While no conclusive evidence exists as yet for the formation of these opiate 
alkaloids directly from THP in vivo, the efficacy of THP in eliciting a volitional drinking 
response in experimental animals is well documented. Myers and Melchior reported 
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initially that ICV infusions of THP would induce spontaneous volitional consumption of 
relatively high concentrations of ethanol by Sprague-Dawley rats, an inbred strain that 
normally avoids even low levels of ethanol [53-55]. Perfusion cannulae were implanted 
in the lateral ventricle of rats by stereotaxic surgery. Figure 10 shows a cutaway diagram 
of the lateral ventricles (marked as LV) of a rat. It should be noted that the lateral 
ventricles serve as a reservoir of cerebrospinal fluid (CSF) for most of the medial 
forebrain bundle. 
Figure 10: A Sagittal Cutaway Diagram of a Rat Brain Showing the Lateral 
Ventricle (LV) and Other Prominent Brain Features 
The animals were then screened for alcohol preference using a three-bottle, 
twelve-day test. The bottle positions were randomized every day. One bottle was empty, 
the second contained water, and the third contained an ethanol solution in water. The 
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alcohol concentration was gradually increased from 3% by volume to 30% by volume 
over the twelve-day period [53]. Once baseline alcohol consumption for each animal was 
established, the pool of experimental rats was divided into two groups. One group was 
given ICV injections of a relatively high concentration of a racemic mixture of THP, and 
the other given a low dosage of racemic THP. The S-(-)-isomer was also tested. The ICV 
injections were made every fifteen minutes around the clock for fourteen days. 
The rats were then screened for alcohol preference using the same initial method. 
Drastic changes were noted in all of the rats' drinking preferences. Halfway through the 
twelve-day protocol, rats that avoided even low concentrations of alcohol drank 
increasing amounts [53]. Rats receiving the concentrated injections of THP increased 
their alcohol consumption to half of their daily fluid intake [53]. Rats receiving the low 
concentration doses of THP drank alcohol in concentrations of up to 25% by volume 
[53]. These changes persisted until the end of the twelve-day protocol, with some 
animals' blood ethanol levels reaching 0.2% [53]. Symptoms of intoxication such as 
ataxia were noted in these animals that drank heavily, as well as symptoms of withdrawal 
when these rats were not drinking ethanol, such as tremors, hyperactivity, rearing, 
chewing, and jerking motions [53]. 
Another team of researchers [56] replicated this experiment. They confirmed that 
ICV injections of 5.2 to 41.6 nmoles/day is sufficient to elevate a Sprague-Dawley rat's 
alcohol consumption but that doses of 104 nmoles/day produced an aversion to ethanol 
[56]. It was also reported that the highest volumes of alcohol consumption occurred when 
the alcohol solution was 11% to 15% by volume [56]. This group of rats refused higher 
concentrations of ethanol and their blood alcohol levels did not reach intoxication, 
16 
although some animals did develop seizures [56]. No other symptoms of intoxication or 
withdrawal were reported. THP-induced changes in alcohol preference in Sprague-
Dawley rats have been found to be very long lasting [53, 56, 57]. They may even be 
permanent, as animals injected with THP tested ten months later still exhibited a strong 
alcohol preference [56]. 
These studies [53, 56-59] suggest a possible role for THP in the etiology of 
ethanol craving. However, it remains to be seen whether THP acts as a false transmitter, 
or as a morphine precursor. All available evidence revolves around the treatment of 
experimental animals with morphine [60-72] or opiate antagonists such as naltrexone 
[73-83] or naltrindole [84, 85]. Morphine has been shown to potentiate alcohol drinking 
in rats with long term effects similar to those for THP-induced alcoholism [74]. Naloxone 
and naltrindole have been reported to reduce the alcohol intake of rats that prefer alcohol 
[63, 70, 74, 86]. So while no clear conclusions about the relationship between THP and 
the opioidergic neural circuits in the brains of mammals can be drawn, the circumstantial 
evidence points to some form of linkage between the two. 
A number of abused drugs, which have independent pharmacological effects and 
are otherwise classified as having separable sites and mechanism of action, all activate 
the mesolimbic dopamine path. Drugs as diverse as cocaine, alcohol, nicotine, and 
heroin have been shown to release dopamine from nerve terminals at the nucleus 
accumbens (NAcc) of the basal forebrain [24, 26, 27, 87]. Pretreatment with naloxone, an 
opioid antagonist which shows higher affinity for the \x opioid receptor [88, 89] or with 
naltrindole, a 8 opioid receptor antagonist [90], attenuated the release of dopamine at the 
NAcc evoked by administration of alcohol. Opiate antagonists, naltrexone and naloxone 
17 
have also been found to suppress volitional alcohol consumption initiated by THP 
infusion [74, 91, 92]. 
Mapping studies [93-95] have found that the ventral tegmental area (VTA) and 
the nucleus accumbens are among the most behaviorally responsive sites to THP 
microinfusion. Of the THIQ alkaloids, THP appears to be the most potent releaser of 
dopamine at forebrain sites, including the NAcc [96]. More recently, microinjections of 
THP into the VTA were found to augment extracellular efflux of dopamine from the core 
of the NAcc [97] of high ethanol preferring (HEP) rats. Conversely, THP suppressed 
dopamine efflux from the shell of the NAcc. Collectively, this evidence suggests that 
THP might exert behavioral actions via modulation of the mesolimbic dopamine circuit. 
While this hypothesis is supported by some investigators, others view THP-
induced alcohol consumption in experimental animals as a pharmacological effect [98, 
99]. These researchers call into question whether THIQ alkaloids are ever formed 
endogenously in quantities sufficient to exert a significant effect on the behavior of the 
animal. Still other researchers have called into question techniques used by investigators 
that have been able to simulate alcoholism using THIQ's such as THIQ purity, surgical 
techniques, dosing regimens, and animal care protocols [60, 100-102]. 
Nonetheless, there1 are few known compounds that exert such a profound effect on 
volitional consumption of alcohol. At the least, these compounds may have utility in 
probing sites and mechanisms in the central nervous system (CNS) involved in the 
mediation or control of alcohol consumption. 
Increases in alcohol consumption have been reported previously following central 
injection of racemic THP as well as the (S)-enantiomer of THP [53]. Heretofore there 
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have not been any published reports of alterations in alcohol preference induced by the 
(R)-enantiomer of THP. The (S)-enantiomer has been proposed to be a major precursor 
of morphine in the opium poppy [31]. It has been proposed that R-(+)-THP could be 
converted to morphine via a racemization reaction [103-107] and low doses of morphine 
have been found to promote alcohol consumption [64, 67, 70, 86, 108-110]. 
The (S)-enantiomer has been detected in the striatum of rats fed alcohol ad 
libitum for 18 months, suggesting that a THP biosynthetic pathway exists in the 
mammalian brain [111]. Moreover, a stereochemical analysis reported the presence of S-
(-)-THP, but not R-(+)-THP, in each of four human brains [51]. Thus, further 
investigation of the (R)-enantiomer may yield additional pertinent information. If R-(+)-
THP has no effect on alcohol consumption, then one might expect S-(-)-THP to be twice 
as effective as the racemic mixture. 
On the contrary, prior reports have not found substantial differences in efficacy 
between S-(-)-THP and racemic THP [53]. This suggests that the (R)-enantiomer should 
be capable of stimulating alcohol consumption. Alternative to the hypothesis that 
morphine is synthesized from the alkaloid, THP may act as an opiate agonist. Because of 
the relative symmetry of the molecule, receptors may be unable to distinguish between 
the two alkaloid isomers. In either scenario, one might expect each enantiomer to be 
equally effective. 
Experiments were conducted to re-evaluate whether, and to what degree, centrally 
administered (±)-THP or (+)-THP might induce alcohol consumption. Additional 
experiments evaluated whether simple repeated exposure to increasing concentrations of 
alcohol might result in volitional drinking. Control groups were used to evaluate whether 
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the stereotaxic procedure itself could impair the ability of the animal to discriminate 
between alcohol and water. 
CHAPTER II 
EXPERIMENTAL 
HPLC Resolution of the Enantiomers of Dihydroxyphenylalanine and Selected Salsolinol 
Derivatives Using Sulfated P-Cyclodextrin as a Chiral Mobile Phase Additive 
Reagents 
Racemic and optically active salsolinol was prepared in our laboratory using 
routes described in the literature [112]. Briefly, condensation of 3,4-
dimethoxyphenethylamine, the dimethoxy analog of dopamine, with acetic anhydride, 
subsequent cyclization to l-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline, followed by 
reduction with sodium borohydride in ethanol gave salsolidine (Figure 11), the 
dimethoxy analog of salsolinol. 
Figure 11: Structure of (A) S-(-)-salsolidine; (B) R-(+)-salsolidine 
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Demethylation of salsolidine in boiling concentrated hydrobromic acid gave 
racemic salsolinol in analytical purity. Resolution of salsolidine followed by hydrobromic 
acid catalyzed demethylation provided the optical isomers of salsolinol (Figure 12). 
Figure 12: Structure of (A) S-(-)-salsolinoI; (B) R-(+)-salsolinoI 
L-DOPA and racemic DL-DOPA (Figure 13) were obtained from commercial 
sources (Sigma-Aldrich, St. Louis, MO). 
Figure 13: Structure of (A) L-(-)-DOPA; (B) D-(+)-DOPA 
The 3-carboxy-tetrahydroisoquinoline derivatives were prepared by reaction of L-
DOPA or racemic DL-DOPA with acetaldehyde to give, respectively, L-3-
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carboxysalsolinol and DL-3-carboxysalsolinol (Figure 14). Crystallization during work-
up provided the cis isomers as the major product [113]. 
i^cooi + CH3CHO 
NHfe 
B 
+ CH3CHO 
NH> 
Figure 14: Condensations of (A) L-DOPA with Acetaldehyde to Form L-3-
Carboxysalsolinol; (B) D-DOPA with Acetaldehyde to Form D-3-Carboxysalsolinol 
+ CH.COCOOH 
Nhfe 
H3C COOH 
Figure 15: Condensation of Dopamine with Pyruvic Acid to Form a Racemic Mix of 
1-Carboxysalsolinol 
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Racemic 1-carboxysalsolinol was synthesized in our laboratory using the reaction 
of dopamine with pyruvic acid (Figure 15) as described in the literature [114]. 
Sulfated P-cyclodextrin (lot number 09718HR) was purchased from Aldrich 
Chemical Co. Sulfated P-cyclodextrin is a cyclic sugar made up of seven glucose units 
joined "head-to-tail" by alpha-1,4 linkages and has several (13-19) of the 21 inner and 
outer rim hydroxyl groups converted to sulfate functionalities (Figure 16) [115-117]. 
Figure 16: Two Views of Sulfated P-Cyclodextrin (A) Side View; (B) Front as Seen 
From the Smaller Diameter "Inner" Rim 
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While direct molecular weight measurements were not available, carbon-
hydrogen analysis values provided by the vendor indicated an average molecular weight 
of 3,000 Daltons. 
Chromatography 
An isocratic HPLC consisting of a micrometering pump (Rainin XLS), a valve-
loop injector (Rheodyne 7125), a variable UV detector (PE SpectroMonitor III) set to 
measure absorbance at 280 nm, and a column oven (PE) were used in these studies. 
Subambient column temperatures were maintained using stirred water baths. 
Econosphere (4.6 mm ID x 250 mm, 5 jam ODS) and Adsorbosphere HS (4.6 mm ID x 
150 mm, 3 um ODS) reversed-phase columns, purchased from Alltech Associates (Grace 
Davison, Deerfield, IL) were employed. Econosphere columns were used primarily to 
chromatograph salsolinol while Adsorbosphere columns, which have greater carbon 
loading were used for the carboxylated substances. 
Mobile phases consisted of 0.05 M phosphoric acid with the pH adjusted to a 
value of 2.5 with sodium hydroxide. No adverse effects were noted from the use of 
acidic mobile phases. Sulfated P-cyclodextrin was added as indicated in the text, to give 
solutions of 0 to 2 mM. Concentrations greater than 1 mM for Econosphere columns and 
2 mM for Adsorbosphere columns gave retention times very near the void retention time, 
t0. Columns were equilibrated by passing 15 to 20 column volumes of mobile phase 
through them before measurements were made. 
Capacity factor, k', values were determined using the formula, 
*' = (tr - to)/t0, (Eqn. 1) 
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where tr is the retention time of an analyte peak and t0 the retention time of an unretained 
solute, obtained using injections of solutions of NaNC>3 or NaNC^. 
Resolution, Rs, was determined using the equation, 
Rs = 2At/(wj + w2), (Eqn. 2) 
where Atr is the difference in retention times between peaks and wi and W2 are the widths 
of the peaks of the two enantiomers. 
Selectivity, a, was calculated using the equation, 
a = k'2/k'i, (Eqn. 3) 
where the k' values are for two peaks of interest. 
Thermodynamics 
Thermodynamics operating during the chromatographic process were assessed 
using the van't Hoff expression [118, 119], 
Ink' = (-AH/RT) + (AS/R) + ln(/>. (Eqn. 4) 
In this expression k' is the capacity factor, R the gas constant, AH and AS the enthalpy 
and entropy of transfer of the solute from the mobile to the stationary phase, and § the 
volume phase ratio of the stationary and mobile phases. The value of 0.385 was used to 
approximate ty as suggested by Sander and Field for octadecasilyl (ODS) packings [120]. 
Approximately the same value for <|> was obtained when the method described by Cole 
and Dorsey [118, 119, 121] was used together with values of percentage carbon loading 
and mass of packing in a typical column obtained from the manufacturer. 
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Plots of Ink' vs. 1/T were obtained. Slopes of these lines were taken to be equal to 
-AH/R and the intercept to be equal to (AS/R) + ln<|). Uncertainties in (j) should affect all 
AS measurements equally. 
A Re-evaluation of the Role of Tetrahydropapaveroline in 
Ethanol Consumption in Adult Male Sprague-Dawley Rats 
Subjects 
Thirty-one (31) male Sprague-Dawley rats (Harlan, Indianapolis, IN) obtained 
from the Frederick, MD plant, weighing between 280 and 340 g at the time of surgery, 
were used for this experiment. Animals were housed individually in hanging 11 inch by 
15 inch wire cages on a reversed 12:12 light/dark cycle with light onset at 20:00. Food 
was available ad libitum. Room temperature was maintained at 23 ± 1 °C. All 
procedures involving animals were conducted in accordance with the NIH Guidelines for 
the Care and Use of Laboratory Animals and the guidelines set forth by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Southern Mississippi 
(APPENDIX). 
Drug Preparation 
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Artificial cerebrospinal fluid was used as a vehicle solution for all experimental 
injections. A liter of artificial cerebrospinal fluid (aCSF) was made containing 7.46 g 
NaCl, 0.19 g KC1, 0.14 g CaCl2, and 0.19 g MgCl2 dissolved in deionized water to which 
was added 0.1 g ascorbic acid to retard the oxidation of THP. The aCSF was filtered 
through a 0.2 urn nylon filter. The THP used in these experiments was synthesized in 
our laboratory (Figure 17) [122-124]. Optically pure R-(+)-THP was synthesized in our 
laboratory by Kenneth D. McMurtrey using established methods [125]. 
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Figure 17: Synthesis of Racemic Tetrahydropapaveroline Hydrobromide 
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NMR Analysis 
A 350 MHz Bruker NMR was used to obtain proton nuclear magnetic resonance 
spectra for R-(+)-THP in D2O to obtain proof positive that our sample is in fact THP. 
Chiral and Achiral HPLC Analysis 
Samples of synthesized R-(+)-THP were chromatographed using both achiral and 
chiral reversed phase HPLC with a UV detector. An isocratic HPLC consisting of a 
micrometering pump (Rainin XLS), a valve-loop injector (Rheodyne 7125), and a 
variable UV detector (PE SpectroMonitor III) set to measure absorbance at 280 nm. The 
columns used were common octadecasilyl Luna (4.6 mm ID x 150 mm, 5um ODS-2), 
and Prodigy (4.6 mm ID x 150 mm, 5um ODS-2) reversed-phase columns, purchased 
from Phenomenex via Alltech Associates. 
The mobile phase used for achiral analysis was 75 % 0.05 M phosphoric acid: 
25% acetonitrile with the pH adjusted to a value of 2.5 with sodium hydroxide. The 
mobile phase used for chiral analysis was 90 % 0.05 M phosphoric acid: 10% methanol 
with the pH adjusted to a value of 3.0 with sodium hydroxide. S-(3-CD was then added to 
this mobile phase in the amount of 2.0 g/L. These achiral and chiral mobile phases were 
used in concert to assay both the identity and the enantiomeric excess of our R-(+)-THP 
sample. In each case, the column was equilibrated by passing 15 to 20 column volumes 
of mobile phase through it before measurements were made. 
Grouping of Experimental Animals 
The Sprague-Dawley rats were split into experimental groups. Animals in one 
group received one of two doses of racemic THP in the amount of 0.65 ug/uL (n=6) or 
1.3 ug/uL (n=4) in aCSF. All other reagents were purchased from Sigma (St. Louis, 
MO). A counterpart solution of (+)-THP was prepared in a similar fashion. A second 
group of animals received one of two doses of the (+)-THP, either 0.66 ng/uL (n=8) or 
1.4 |ag/uL (n=4) in aCSF. Controls received either aCSF containing no racemic THP or 
(+)-THP, or no injections at all (n=9). 
Alcohol Preference Testing 
This experiment utilized the two-choice, three-bottle free access paradigm [126] 
of exposure to incremental concentrations of alcohol (3 to 30% over twelve days). Three 
calibrated 100 mL drinking tubes were positioned equidistantly at the front of each 
animal's cage. One tube contained a solution of ethanol in which the concentration was 
increased daily in the following manner: 3, 4, 5, 6, 7, 9, 11, 13, 15, 20, 25, and 30 
percent alcohol by volume. Each solution was prepared with 95% ethanol (Everclear 
drinking spirits) and distilled water. A second tube contained only water and the third 
tube was empty. 
These tubes were rotated each day according to a predetermined random sequence 
to prevent the development of a position habit. By raising the concentration of the 
ethanol offered, a baseline preference or aversion was established for each animal. Daily 
measures of alcohol and water consumption were taken at 16:00. To evaluate the 
possibility of fluid loss due to evaporation, an empty cage was fitted daily with the 
appropriate fluids. Metal trays lined with newsprint were carefully inspected (and 
replaced) daily for evidence of fluid spillage. Loss of fluid due to evaporation and 
spillage was negligible. 
Intraventricular Administration ofTHP 
Each rat was anesthetized with ketamine: xylazine anesthesia (25:5 mg/kg or 1 
mL/kg body weight; IP Figure 18) prior to stereotaxic surgery. 
Figure 18: Intraperitoneal (IP) Injection of Anesthetic 
Once anesthesia was confirmed via tail and foot pinch, the animal's head was 
shaved and placed into a Kopf stereotaxic instrument (Figure 19) with the head centered 
and the incisor bar set 3.0 mm above the interaural line. 
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Figure 19: Schematic of a Kopf Stereotaxic Surgical Instrument 
A stainless steel (22 ga., 13 mm in length) guide cannulae (Small Parts Inc., 
Miami Lakes, FL) was affixed to the probe holder of the Kopf apparatus. A small (ca. 1.5 
inches) longitudinal incision was made in the scalp with a scalpel. The incision was held 
open by hemostats. The fascia was then scraped away to reveal the skull. The skull is 
wiped and dried with surgical gauze and any bleeding is stopped with a surgical cautery 
(Aaron, Inc.). 
The tip of the guide cannula was placed at bregma, a landmark feature of the skull 
where the sagittal and coronal sutures meet (Figure 20). 
Figure 20: Schematic of Landmark Features Found on the Rat Skull 
Once bregma was located, the guide cannula tip was positioned above the lateral 
ventricles according to Paxinos and Watson [127]. The coordinates from bregma were: 
AP -0.5 mm; ML 1.5 mm; flat skull [127]. A mark was made at this point with a No. 2 
pencil. A burr hole was drilled through the skull at this mark. The guide cannula was 
swung aside on the boom arm and small surgical anchor screws (available from Small 
Parts, Inc.) were inserted into the calvarium (Figure 21). 
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Figure 21: Photograph of Placement of Stereotaxic Anchor Screws 
The guide cannula was inserted into the skull through the burr hole and lowered 
3.0 mm to the lateral ventricle of the animal [127]. Cranioplastic cement (Lang Dental) 
was packed around the screws and guide cannulae in a pedestal shape to fix them all in 
place. The incision was then closed around the pedestal with standard silk surgical 
sutures. 
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ICV Injections 
Dummy cannulae (28 ga. stainless steel tubing from Small Parts, Inc.) were 
prefitted to extend 0.5 mm beyond the tip of the guide cannula so that the tip of the 
injection cannula rested in the lumen of the lateral ventricle. This prefitted 13.5 mm 
length of 28 ga. stainless steel stylet was then inserted into the guide cannulae to prevent 
obstructions. Injection needles of the same length and material were attached by 
polyethylene tubing to a 50 uL tuberculin HPLC syringe. An automated Harvard 
Apparatus Model PHD 2000 (South Natick, MA) syringe pump was used to deliver 
intracerebroventricular (ICV) infusions of drug (or vehicle) in a volume of 5 uL per 
infusion over two minutes. Each animal received two injections (09:00 and 16:00) per 
day for three consecutive days. This dosing regimen has been shown previously with 
THP to induce significant increases in alcohol consumption [113]. The first injection 
commenced after a seven day post-surgery recovery period. 
Alcohol Preference Test Scheduling 
A twelve-day alcohol preference test was administered prior to the surgery. A 
second twelve-day alcohol preference post-test was given following the three injection 
days. In a subset of animals, three twelve-day tests were conducted: one sequence prior 
to surgery, a second sequence after surgery but prior to central injections, and the third 
sequence following three days of injections. In a subset of animals (n=15) that had been 
treated with either (±)-THP or (+)-THP, volumetric water and alcohol consumption was 
recorded every four hours around the clock to evaluate the distribution of alcohol and 
water consumption over the course of a 24 hour period. 
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Standard histological techniques were used to verify placement of guide cannulae. 
All animals were sacrificed with a lethal overdose of sodium pentobarbital (Nembutal, 
100 mg/kg BW), and perfused intracardially with 0.9% saline and 10% phosphate-
buffered formalin. The brains were removed and stored in formalin for at least 24 hours. 
Serial coronal sections (40 urn) were made in a cryostat (Microm HM 505 N) at -30 °C 
through the site of implant onto gelatinized glass slides which were stained with cresyl 
violet dye, then coverslipped. Cannula tip placements were visually compared to line 
drawings from a stereotaxic atlas [127]. 
Statistical Analyses 
All analyses were conducted using SPSS software. All values are expressed as 
mean ± SEM. The a level of significance used for all statistical tests was/? < 0.05. A 
one-way ANOVA for independent groups was used to compare the three control 
conditions: vehicle-treated animals, sham-operated animals, and naive animals. A 
mixed-model ANOVA (drug treatment over days) was used to analyze the effect of drug 
treatment. The Huyn-Feldt correction was used since there was a violation of the 
assumption of sphericity. Tukey's HSD post-hoc tests were used to compare treatment 
conditions. To evaluate whether differences in alcohol consumption were significant on 
each day, 95% confidence intervals were determined around the mean of the control 
condition for each day. To evaluate whether repeated exposure to alcohol caused any 
alteration in alcohol consumption, a one-way ANOVA for repeated measures was used 
on animals that had completed three consecutive twelve-day preference tests without 
receiving a drug treatment. 
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A Re-evaluation of the Role of Tetrahydropapaveroline in 
Ethanol Consumption in Another Population of Adult Sprague-Dawley Rats 
Subjects 
Subsequent to the first round of treatments performed on rats obtained from the 
Frederick, MD plant, ten (10) male Sprague-Dawley rats (Harlan, Indianapolis, IN) from 
the Prattville, AL plant weighing between 280 and 340 g at the time of surgery, were 
used for this experiment. All conditions with regards to housing, light cycle, temperature, 
and animal care were identical to the previous ICV experiment involving rats obtained 
from the Harlan site in Frederick, MD. All procedures involving animals were conducted 
in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals and 
the guidelines set forth by the Institutional Animal Care and Use Committee (IACUC) of 
the University of Southern Mississippi (APPENDIX). 
Drug Preparation 
Artificial cerebrospinal fluid was used as a vehicle solution for all experimental 
injections. A liter of artificial cerebrospinal fluid (aCSF) was prepared in the same 
manner as the previous ICV experiment involving rats obtained from the Harlan site in 
Frederick, MD. The aCSF was filtered through a 0.2 um nylon filter. The THP used in 
these experiments was synthesized in our laboratory (Figure 17) [122-124]. Optically 
pure R-(+)-THP was synthesized in our laboratory by Kenneth D. McMurtrey using 
established methods [125]. All other reagents were purchased from Sigma (St. Louis, 
MO). 
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Grouping of Experimental Animals 
One group of animals received a dose of racemic THP in the amount of 0.65 
ug/uL in aCSF. A counterpart solution of R-(+)-THP was prepared in a similar fashion. 
A second group of animals received a dose of aCSF containing (+)-THP in the amount of 
0.67 ug/uL. Control animals received aCSF containing no THP. 
Animals in the first group received racemic THP in the amount of 0.65 ug/uL in 
aCSF (n=3). A counterpart solution of R-(+)-THP was prepared in a similar fashion. A 
second group of animals received R-(+)-THP in the amount 0.67 ug/uL in aCSF (n=3). 
Controls received either aCSF containing no THP (n=2), or no injections at all (n=2). 
Alcohol Preference Testing 
This experiment utilized the two-choice, three-bottle free access paradigm [126] 
of exposure to incremental concentrations of alcohol (3 to 30% over twelve days). Three 
calibrated 100 mL drinking tubes were positioned equidistantly at the front of each 
animal's cage. One tube contained a solution of ethanol in which the concentration was 
increased daily in the following manner: 3, 4, 5, 6, 7, 9, 11, 13, 15, 20, 25, and 30 
percent alcohol by volume. Each solution was prepared with 95% alcohol (Everclear 
drinking spirits) and distilled water. A second tube contained only water and the third 
tube was empty. These tubes were rotated each day according to a predetermined 
random sequence to prevent the development of a position habit. By raising the 
concentration of the ethanol offered, a baseline preference or aversion was established for 
each animal. Daily measures of alcohol and water consumption were taken at 16:00. To 
evaluate the possibility of fluid loss due to evaporation, an empty cage was fitted daily 
with the appropriate fluids. Metal trays lined with newsprint were carefully inspected 
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(and replaced) daily for evidence of fluid spillage. Loss of fluid due to evaporation and 
spillage was negligible. 
Intracerebroventricular Administration ofTHP 
Each rat was anesthetized with ketamine: xylazine anesthesia (25:5 mg/kg or 1 
mL/kg body weight; IP) prior to stereotaxic surgery. Once anesthesia was confirmed via 
tail and foot pinch, the animal was shaved and placed into a Kopf stereotaxic instrument 
with the head centered and the incisor bar set 3.0 mm above the interaural line. 
A stainless steel (22 ga., 13mm in length) guide cannulae (Small Parts Inc., 
Miami Lakes, FL) was affixed to the probe holder of the Kopf apparatus. A small (ca. 1.5 
inches) longitudinal incision was made in the scalp with a standard surgical scalpel. The 
incision was held open by hemostats. The fascia was then scraped away to reveal the 
skull. The skull is wiped and dried with surgical gauze and any bleeding is stopped with a 
surgical cautery. 
The tip of the guide cannula was placed at bregma, a landmark feature of the skull 
where the sagittal and coronal sutures meet. Once bregma was located, the guide cannula 
tip was positioned above the lateral ventricles according to Paxinos and Watson [127]. 
The coordinates from bregma were: AP -0.5 mm; ML 1.5 mm; flat skull [127]. A mark 
was made at this point with a No. 2 pencil. A burr hole was drilled through the skull at 
this mark. The guide cannula was swung aside on the boom arm and small surgical 
anchor screws (available from Small Parts, Inc.) were inserted into the calvarium. 
The guide cannula was inserted into the skull through the burr hole and lowered 
3.0 mm to the lateral ventricle of the animal. Cranioplastic cement (Lang Dental) was 
packed around the screws and guide cannulae in a pedestal shape to fix them all in place. 
39 
ICV Injections 
Dummy cannulae (28 ga. stainless steel tubing from Small Parts, Inc.) were 
prefitted to extend 0.5 mm beyond the tip of the guide cannula so that the tip of the 
injection cannula rested in the lumen of the lateral ventricle. This prefitted 13.5 mm 
length of 28 ga. stainless steel stylet was then inserted into the guide cannulae to prevent 
obstructions. Injection needles of the same length and material were attached by 
polyethylene tubing to a 50 uL tuberculin HPLC syringe. An automated Harvard 
Apparatus Model PHD 2000 (South Natick, MA) syringe pump was used to deliver 
intracerebroventricular (ICV) infusions of drug (or vehicle) in a volume of 5 uL per 
infusion over 2 minutes. Each animal received two injections (09:00 and 16:00) per day 
for three consecutive days. This dosing regimen has been shown previously with THP to 
induce significant increases in alcohol consumption [113]. The first injection 
commenced after a seven day post-surgery recovery period. 
Alcohol Preference Test Scheduling 
A twelve-day alcohol preference test was administered prior to the surgery. A 
second twelve-day alcohol preference post-test was given following the three injection 
days. In a subset of animals, three twelve-day tests were conducted (n=T0): one 
sequence prior to surgery, a second sequence after surgery but prior to central injections, 
and the third sequence following three days of injections. In a subset of animals (n=15) 
that had been treated with either THP racemate or R-(+)-THP, volumetric water and 
alcohol consumption was recorded every four hours around the clock to evaluate the 
distribution of alcohol and water consumption over the course of a 24 hour period. 
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Standard histological techniques were used to verify placement of guide cannulae. 
All animals were sacrificed with a lethal overdose of sodium pentobarbital (Nembutal, 
100 mg/kg BW), and perfused intracardially with 0.9% saline and 10% phosphate-
buffered formalin. The brains were removed and stored in formalin for at least 24 hours. 
Serial coronal sections (40 urn) were made in a cryostat (Microm HM 505 N) at -30 °C 
through the site of implant onto gelatinized glass slides which were stained with cresyl 
violet dye, then coverslipped. Cannula tip placements were visually compared to line 
drawings from a stereotaxic atlas [127]. 
Statistical Analyses 
All analyses were conducted using SPSS software. All values are expressed as 
mean ± SEM. The a level of significance used for all statistical tests was p < 0.05. A one-
way ANOVA for independent groups was used to compare the control conditions. A 
mixed-model ANOVA (drug treatment over days) was used to analyze the effect of drug 
treatment. The Huyn-Feldt correction was used since there was a violation of the 
assumption of sphericity. Tukey's HSD post-hoc tests were used to compare treatment 
conditions. To evaluate whether differences in alcohol consumption were significant on 
each day, 95% confidence intervals were determined around the mean of the control 
condition for each day. To evaluate whether repeated exposure to alcohol caused any 
alteration in alcohol consumption, a one-way ANOVA for repeated measures was used 
on animals that had completed three consecutive twelve-day preference tests without 
receiving a drug treatment. 
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An Evaluation of the Role of 2,3,10,11 -Tetrahydroxyberbine in 
Ethanol Consumption in Adult Male Sprague-Dawley Rats 
Subjects 
Eleven (11) male Sprague-Dawley rats (Harlan, Indianapolis, IN) obtained from 
the Frederick, MD plant, weighing between 280 and 340 g at the time of surgery, were 
used for this experiment. All conditions with regards to housing, light cycle, temperature, 
and animal care were identical to the previous experiments involving ICV injections of 
THP. All procedures involving animals were conducted in accordance with the NIH 
Guidelines for the Care and Use of Laboratory Animals and the guidelines set forth by 
the Institutional Animal Care and Use Committee (IACUC) of the University of Southern 
Mississippi (APPENDIX). 
Drug Preparation 
Artificial cerebrospinal fluid was used as a vehicle solution for all experimental 
injections. A liter of artificial cerebrospinal fluid (aCSF) was prepared in the same 
manner as the previous experiments involving ICV injections of THP. Ascorbic acid was 
added in the amount of 0.1 g to retard the oxidation of THB (structure depicted in Figure 
22). The aCSF was filtered through a 0.2 um nylon filter. The THB used in these 
experiments was synthesized in our laboratory according to methods found in the 
literature [123, 124]. All other reagents were purchased from Sigma (St. Louis, MO). 
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Figure 22: Structure of THB 
Animals received a dose of THB in the amount of 0.65 [ig/[iL in aCSF (n=6) in 
the form of 5 ^L over a period of two minutes. Control animals received aCSF containing 
no THB in the same volume and time period (n=4). 
Alcohol Preference Testing 
This experiment utilized the two-choice, three-bottle free access paradigm [126] 
of exposure to incremental concentrations of alcohol (3 to 30% over twelve days). Three 
calibrated 100 mL drinking tubes were positioned equidistantly at the front of each 
animal's cage. One tube contained a solution of ethanol in which the concentration was 
increased daily in the following manner: 3, 4, 5, 6, 7, 9, 11, 13,15, 20, 25, and 30 
percent alcohol by volume. Each ethanol solution was prepared with 95% alcohol 
(Everclear drinking spirits) and distilled water. A second tube contained only water and 
the third tube was empty. These tubes were rotated each day according to a 
predetermined random sequence to prevent the development of a position habit. 
By raising the concentration of the ethanol offered, a baseline preference or 
aversion was established for each animal. Daily measures of alcohol and water 
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consumption were taken at 16:00. To evaluate the possibility of fluid loss due to 
evaporation, an empty cage was fitted daily with the appropriate fluids. Metal trays lined 
with newsprint were carefully inspected (and replaced) daily for evidence of fluid 
spillage. Loss of fluid due to evaporation and spillage was negligible. 
Intracerebroventricular Administration ofTHB 
Stainless steel (22 ga., 13mm in length) guide cannulae (Small Parts, Miami 
Lakes, FL) were stereotaxically implanted into the right lateral ventricle of each rat under 
ketamine: xylazine anesthesia (25:5 mg/kg body weight; IP) seven days prior to the 
beginning of central injections. The coordinates from bregma were AP -0.5 mm; ML 1.5 
mm; flat skull [127]. After anchor screws (available from Small Parts, Inc.) were 
inserted into the calvarium, cranioplastic cement (Lang Dental) was packed around the 
screws and guide cannulae to fix them in place. 
Dummy cannulae (28 ga. stainless steel tubing, Small Parts, Inc.) were prefitted 
to extend 0.5 mm beyond the tip of the guide cannula so that the tip of the injection 
cannula rested in the lumen of the lateral ventricle. These prefitted 13.5 mm lengths of 28 
ga. stainless steel stylets were then inserted into the guide cannulae to prevent 
obstructions. 
Injection needles of the same length were attached by polyethylene tubing to a 
50 pL tuberculin HPLC syringe. An automated Harvard Apparatus Model PHD 2000 
(South Natick, MA) syringe pump was used to deliver intracerebroventricular (ICV) 
infusions of drug (or vehicle) in a volume of 5 uL per infusion over 2 minutes. Each 
animal received two injections (09:00 and 16:00) per day for three consecutive days. 
This dosing regimen has been shown previously with THP to induce significant increases 
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in alcohol consumption [113]. The first injection day commenced after a seven day post-
surgery recovery period. 
A twelve-day alcohol preference test was administered prior to the surgery. A 
second twelve-day alcohol preference post-test was given following the three injection 
days. Standard histological techniques were used to verify placement of guide cannulae. 
All animals were sacrificed with a lethal overdose of sodium pentobarbital (Nembutal, 
100 mg/kg BW), and perfused intracardially with 0.9% saline and 10% phosphate-
buffered formalin. The brains were removed and stored in formalin for at least 24 hours. 
Serial coronal sections (40 urn) were made in a cryostat (Microm HM 505 N) at -30 ° C 
through the site of implant onto gelatinized glass slides which were stained with cresyl 
violet dye, then coverslipped. Cannula tip placements were visually compared to line 
drawings from a stereotaxic atlas [127]. 
Statistical Analyses 
All analyses were conducted using SPSS software. All values are expressed as 
mean±SEM. The a level of significance used for all statistical tests was p< 0.05. A 
one-way ANOVA for independent groups was used to compare the control conditions. A 
mixed-model ANOVA (drug treatment over days) was used to analyze the effect of drug 
treatment. The Huyn-Feldt correction was used since there was a violation of the 
assumption of sphericity. Tukey's HSD post-hoc tests were used to compare treatment 
conditions. To evaluate whether differences in alcohol consumption were significant on 
each day, 95% confidence intervals were determined around the mean of the control 
condition for each day. To evaluate whether repeated exposure to alcohol caused any 
alteration in alcohol consumption, a one-way ANOVA for repeated measures was used 
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on animals that had completed three consecutive twelve-day preference tests without 
receiving a drug treatment. 
Investigation of the Effects of Ethanol Consumption on Tetrahydropapaveroline Levels in 
the Cerebrospinal Fluid of Adult Male Sprague-Dawley Rats Using Microdialysis and 
High Pressure Liquid Chromatography with Electrochemical Detection 
Subjects 
Three (3) male Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing 
between 280 and 340 g at the time of surgery, were used for this experiment. Animals 
were housed individually in hanging 11 inch X 15 inch wire cages on a reverse 12:12 
light/dark cycle with light onset at 20:00. Food was available ad libitum. Room 
temperature was maintained at 23 ± 1 ° C. All procedures involving animals were 
conducted in accordance with the NIH Guidelines for the Care and Use of Laboratory 
Animals and the guidelines set forth by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Southern Mississippi (APPENDIX). 
Implantation of Microdialysis Probe Guide Cannulae 
Stainless steel (21.5 ga., 13 mm in length) guide cannulae (Small Parts, Miami 
Lakes, FL) were stereotaxically implanted into the right lateral ventricle of each rat under 
ketamine: xylazine anesthesia (25:5 mg/kg body weight; IP) seven days prior to the 
beginning of microdialysis sampling. The coordinates from bregma were AP -0.5 mm; 
ML 1.5 mm; flat skull [127]. After anchor screws (available from Small Parts, Inc.) were 
inserted into the calvarium, cranioplastic cement (Lang Dental) was packed around the 
screws and guide cannulae to fix them in place. 
Dummy cannulae (28 ga. stainless steel tubmg, Small Parts, Inc.) were prefitted to 
extend 0.5 mm beyond the tip of the guide cannula so that the tip of the dummy cannula 
would rest in the lumen of the lateral ventricle. These prefitted 13.5 mm lengths of 28 ga. 
stainless steel stylets were inserted into the guide cannulae to prevent obstructions. 
Microdialysis Recovery Determination 
In order to determine the optimal flow rate for microdialysis experiments, a 
simulation of microdialysis conditions was conducted. A 2mL aliquot of a 0.69 uM 
solution of THP in aCSF was placed in a 3 mL vial for each flow rate trial. A CMA/11 
microdialysis probe with a 2.0 mm cuprophane dialysis membrane having a 6,000 Dalton 
cutoff range was placed in the 0.69 uM "parent" solution and perfused with aCSF using a 
Harvard Apparatus syringe pump at 0.5, 1.0, and 1.5 uL/minute. Six 20 uL samples of 
dialysate were collected at each flow rate and THP concentration of each dialysate 
sample was determined using high pressure liquid chromatography with an 
electrochemical detector. 
The HPLC apparatus used consisted of a Rheodyne 7125 injector valve, a Rainin 
XLS delivery pump, a Econosphere (4.6 mm ID x 250 mm 5 urn ODS) HPLC column, 
and a BAS LC-3 amperometric detector using a glassy carbon electrode cell. The 
potential of the working electrode was set to 700 mV. The mobile phase consisted of 
0.05M NH4H2PO4 with a 5% acetonitrile component with a pH of 4.00. 
Microdialysis Sampling of Rat CSF 
An animal holding pen was constructed from a large (ca. 3.5 gallon) plastic 
planting pot available at any garden or home improvement store. The drain holes were 
blocked with a large paper plate and appropriate bedding and food pellets were placed in 
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the pen. Two iron ring stands were placed on either side of the holding pen and a crossbar 
transecting the diameter of the pen was suspended approximately six inches above the 
rim of the pen to act as a tether point for polyethylene tubing and dialysate collection 
vials (Figure 23). A drinking tube filled with water was clamped to one iron ring stand 
and lowered into the pen to provide animals with fluid ad libitum. 
Figure 23: Microdialysis Holding Pen and Support Setup 
A CMA/11 microdialysis probe was connected to a Harvard Apparatus syringe 
pump using approximately one meter of polyethylene tubing and CMA tubing 
connectors. The CMA/11 microdialysis probe is tipped with a 2.0 mm cuprophane 
membrane that allows the diffusion of neurotransmitters into the perfusate solution, aCSF 
prepared in the same fashion as the aCSF used for ICV injections. 
The syringe pump was set to deliver aCSF to the probe at 1.0 uL/min. After a 
visual inspection to insure that the dialysate fluid ran clear and the membrane was not 
perforated, approximately 200 cm of polyethylene collection tubing was connected using 
CMA tubing connectors. After a 30 minute equilibration period, the collection of dialysis 
samples began. Dialysate was collected from each animal in five 20 minute intervals. 
After collection of baseline THP samples for assessment of basal THP levels, rats were 
force fed via a gavage tube 5 mL of 20% ethanol in distilled water ten minutes prior to 
their introduction into the microdialysis chamber and subsequent insertion of the 
CMA/11 probe. 
HPLC Analysis of Ventricular CSF Using Amperometric Electrochemical Detection 
The HPLC apparatus used consisted of a Valco rotary injector valve, a LDC 
delivery pump, an Econosphere (4.6 mm ID x 250 mm, 5 urn ODS) HPLC column, and 
an amperometric detector using a glassy carbon electrode cell. Dr. Newton Fawcett of 
the University of Southern Mississippi chemistry and biochemistry department 
constructed this detector. This amperometric detector was used because of its excellent 
signal to noise ratio. Dr. Fawcett used high-grade gold connector pins, which last much 
longer and yield a better signal than conventional manufacturer components, in the circuit 
design. The potential of the working electrode was set to 700 mV. The mobile phase 
consisted of 0.05M NH4H2P04 buffered to a pH of 3.00 with NaOH. The column was 
flushed after each chromatographic run until THP was no longer detectable to avoid 
carryover into the next sample. 
CHAPTER III 
EXPERIMENTAL RESULTS, DISCUSSION, AND CONCLUSIONS 
Experimental Results on HPLC Resolution of the Enantiomers of 
Dihydroxyphenylalanine and Selected Salsolinol Derivatives Using Sulfated P-
Cyclodextrin as a Chiral Mobile Phase Additive 
Deng and co-workers used P-cyclodextrin (P-CD) in combination with ion-
pairing reagents such as sodium heptyl sulfate to separate the stereoisomers of salsolinol 
[128-131]. They reported modest maximum selectivity of approximately 1.08. This 
experiment examined the use of commercially available sulfated P-cyclodextrin (S-P-
CD) and demonstrates that it efficiently separates the stereoisomers of salsolinol when 
used alone without heptane sulfate or other ion-pairing reagents. 
Indeed, S-P-CD yields a selectivity of approximately 1.08 at even the very low 
concentration of 0.1 mM, whereas concentrations of about 15 mM are required for P-CD 
and these chiral separations are successful only in the presence of an ion-pairing 
reagent[128-131]. S-P-CD is capable of much greater degrees of separation of salsolinol 
enantiomers than P-CD. This experiment yielded an a value of 1.59 and a resolution of 
3.5 for R-(+)- and S-(-)-salsolinol using 1 mM S-P-CD concentration without an ion-
pairing reagent. Greater concentrations of S-P-CD should provide even greater a and Rs 
values. The limiting factor for salsolinol appears to be the very low retention times 
accompanying the use of higher concentrations of the chiral selector. With a 1 mM 
concentration of S-P-CD the value of k' for (+)-SAL is less than 1. 
Stoichiometry of the complex formed between SAL stereoisomers and sulfated p-
cyclodextrin appears to be 1:1. A study of the effects of increasing S-P-CD concentration 
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on retention of the stereoisomers of SAL indicates that variation of the reciprocal of the 
capacity factors of R-(+)-, and S-(-)-SAL are linear (Figure 24). This is the relationship 
expected if SAL and S-P-CD form a 1:1 complex [132]. 
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Figure 24: Plot of the Reciprocal of the Capacity Factor Versus Varying 
Concentrations of Chiral Mobile Phase Additive 
L-DOPA, D-DOPA and related carboxylated derivatives of salsolinol were 
chromatographed on a Cis reversed phase column with an aqueous mobile phase 
containing varying amounts of the chiral selector, sulfated P-cyclodextrin (S-P-CD). In 
contrast to the linear relationships observed in the case of SAL stereoisomers, the 
carboxyl-substituted compounds give nonlinear curves when 1/k' for these materials is 
plotted against S-P-CD concentration (Figure 25). This nonlinearity is taken as evidence 
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that the equilibrium system between S-p-CD and the carboxylated compounds are more 
complex than that operating for salsolinol [132]. 
Figure 25: Plot of the Reciprocal of Capacity Factor of Chiral Separations of DOPA, 
1-CSAL, and 3-CSAL Versus Chiral Mobile Phase Additive 
In an attempt to gain some insight into the mechanisms that may be operating, the 
effects of temperature on retention of the various carboxylated compounds were 
investigated with a mobile phase containing 2 mM S-P-CD. Representative 
chromatograms of resolution of the compounds studied are given in Figure 26. 
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Figure 26: Representative Chromatograms of Chiral Separations of (A) SAL 
at 20 °C; (B) DOPA at 35 °C; (C) 3-CSAL at 35 °C; (D) 3-CSAL at 0 °C; (E) 1-CSAL 
at 0 °C. All Chromatograms on Same Time Scale With Tick Marks at Five Minute 
Intervals 
Salsolinol separates well at room temperature (trace A) and 3-CSAL gives good 
resolution at 35 °C (trace C). Resolution of D- and L-DOPA is not complete at 35 °C 
(trace B), although resolution improves when the temperature of the column is decreased 
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(not shown). Lower temperatures generally improve resolution. This improvement is 
represented by chromatogram D which is the separation of D- and L-3-CSAL at 0 °C 
with a resolution slightly greater than 5. In contrast 1-CSAL isomers are separated only 
slightly (trace E). Even this degree of separation is achieved only at 0 °C. 
The data obtained were used to prepare van't Hoff plots (Figure 27). The most 
immediately obvious characteristic of these plots are the breaks in the curves immediately 
below room temperature, approximately 15 °C to 20 °C. Curves between 20 °C and 35 °C 
have different slopes and intercepts than those obtained from measurements between 0 °C 
and 13 °C. Different slopes and intercepts indicate differences in AH and AS values. 
When plotted seperately these two sections of the curve have differing slopes, indicating 
different enthalpy and entropy values. The "low temperature" van't Hoff plot appears as 
Figure 28. The "high temperature" van't Hoff plot appears as Figure 29. 
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Figure 27: Van't Hoff Plot for Chiral Separations of Selected Catecholamines 
Showing a Change in Slope Between "High Temperature" and "Low Temperature" 
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Figure 28: Van't Hoff Plot of Low Temperature Seperations of DOPA and 3-
CSAL with 2 mM Chiral Moile Phase Additive S-p-CD 
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Figure 29: Van't Hoff Plot of High Temperature Seperations of DOPA and 3-
CSAL with 2 mM Chiral Moile Phase Additive S-p-CD 
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Van't Hoff curves for the compounds using a mobile phase that did not contain 
the chiral selector were obtained and similar breaks were found. Thermodynamic data 
obtained from the slopes and intercepts of the curves are given in Tables 1-4. As may be 
seen, all thermodynamic variables are negative. Furthermore, absolute values for both 
AH0 and AS0 increase when the temperatures used in their determinations decrease. In all 
cases AH0 values are negative and thus favorable for retention, but in all cases AS0 values 
are also negative and therefore unfavorable. Contributions by unfavorable entropy values 
are more than offset by favorable enthalpy values. 
Table 1: Thermodynamic Variables Associated With Chromatography of the Test 
Substances with Mobile Phase Containing 2 mM S-P-CD Over Relatively High 
Temperatures (20 °C-35 °C) 
Substance 
L-DOPA 
D-DOPA 
L-3-CSAL 
D-3-CSAL 
AH°(kJ/mol) 
- 17.7 
-16.5 
-18.0 
-16.3 
AS°(J/Kmol) 
-45.0 
-41.3 
- 47.0 
-43.3 
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Table 2: Thermodynamic Variables Associated With Chromatography of the Test 
Substances with Mobile Phase Containing 2 mM S-P-CD Over Relatively Low 
Temperatures (0 °C-13 °C) 
Substance 
L-DOPA 
D-DOPA 
L-3-CSAL 
D-3-CSAL 
AH°(kJ/mol) 
-30.7 
-29.3 
-36.0 
-35.2 
AS°(J/Kmol) 
-87.8 
- 84.0 
- 107.8 
- 108.0 
Table 3: Thermodynamic Variables Associated With Chromatography of the Test 
Substances with Mobile Phase Containing no Chiral Selector S-P-CD Over 
Relatively High Temperatures (20 °C-35 °C) 
Substance 
DOPA 
3-CSAL 
1-CSAL 
SAL 
AH°(kJ/mol) 
-18.4 
-18.7 
-15.6 
-15.2 
AS°(J/Kmol) 
-49.1 
-50.0 
-39.2 
-33.2 
Table 4: Thermodynamic Variables Associated With Chromatography of the Test 
Substances with Mobile Phase Containing no Chiral Selector S-P-CD Over 
Relatively Low Temperatures (0 °C-13 °C) 
Substance 
DOPA 
3-CSAL 
1-CSAL 
SAL 
AH" (kJ/mol) 
-33.7 
-34.9 
-34.0 
-22.7 
AS" (J/Kmol) 
- 100.8 
-104.8 
-103.1 
- 57.8 
The breaks in the van't Hoff curves are interpreted in terms of the retention model 
developed by Dorsey and Dill [133]. These data indicate a phase transition in the 
stationary phase hydrocarbon chains occurring over approximately the 15 °C to 20 PC 
range. Such phase transitions in re versed-phase stationary phases are relatively well 
known. They have been described as a "reversible melting-like transition of long-chain 
hydrocarbon ligands" which occur in high bonding density monomeric silica based Cis 
packings in the vicinity of room temperature [119, 134, 135]. 
At higher temperatures the extended chains allow relatively easy penetration of 
solute molecules into the stationary phase while the more compacted chains at lower 
temperature provide less opportunity of solute penetration. The effect is most clearly 
seen in the entropy values. Entropies of retention are double in the negative unfavorable 
direction at lower temperatures than they are at higher ones. Absorption of solute 
molecules by the stationary phase at the lower temperature conformation is more costly 
in terms of the entropy of chain ordering if the chains are more compact at these 
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temperatures. 
The crural compound S-P-CD appears to be an efficient and cost effective chiral 
selector for resolution of salsolinol and 3-carboxysalsolinol optical isomers. However, it 
is less effective for D- and L-DOPA, giving complete resolution only at subambient 
temperatures. It is least effective of all for 1-carboxysalsolinol. Retention of these 
materials is promoted by favorable enthalpies which (except for the case of 1-CSAL) 
more than make up for unfavorable changes in entropy. 
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Experimental Results from ICV Injections of Relevant Compounds on Volitional Ethanol 
Consumption in Adult Male Sprague-Dawley Rats 
THP Characterization by Proton NMR 
A one dimensional proton NMR scan of the sample of R-(+)-THP in D2O yielded 
the following spectrum (Figure 30). 
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Figure 30: Proton NMR Spectrum and Peak Assignments for R-(+)-THP 
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Protons attached to aryl moieties (positions "a", "b", "g", "h", and "i") exhibit the 
greatest chemical shift and show as peaks from 6.7-6.5 ppm. The HDO peak from the 
exchange of labile hydrogen between the analyte and D2O solvent appears, as expected, 
as a large peak at approximately 4.7ppm. A chemical shift of approximately 4.45 ppm is 
observed for the proton in the position "e". Proton "d" is heavily split and shows as a 
multiplet from 3.3-3.1 ppm. Proton "c", attached to the nitrogen-containing portion of the 
molecule, overlaps slightly with proton "f" at approximately 2.8-2.7 ppm. These 
interpretations match those obtainable from the Sadtler Index [136] and those obtained by 
previous researchers [137, 138]. Hence, the identity of this sample of synthesized 
stereoisomer of THP is confirmed. 
HPLC Analysis in Achiral and Chiral Environments 
Injection of samples of R-(+)-THP and racemic THP onto a commercially 
available Cjg ODS HPLC column with an achiral mobile phase yielded the following 
chromatograms (Figure 31). Trace A is a sample of R-(+)-THP dissolved in a solution of 
identical composition as the mobile phase with sodium nitrate added as a to marker. Trace 
B is an identical solution that has been spiked with an additional aliquot of racemic THP. 
The coelution of these compounds from this column indicates that the samples behave 
identically in an achiral environment. This is indicative of extreme similarity in the 
hydrophilic nature of these compounds. 
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Figure 31: Achiral HPLC Chromatographs Showing Retention Times of (A) 
NaN03 and R-(+)-THP; (B) NaNOs, R-(+)-THP, and Racemic THP 
Additionally, samples of R-(+)-THP and racemic THP were injected onto a 
commercially available Cis ODS HPLC column with an chiral mobile phase (2.0 g/L S-P-
CD) yielded the following chromatograms (Figure 32). 
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Figure 32: Representative Chiral HPLC Chromatograms of (A) R-(+)-THP 
and NaN03; (B) NaN03 and THP Racemate; (C) NaN03, THP Racemate, and R-
(+)-THP 
Chromatogram A is a sample of R-(+)-THP dissolved in an aliquot of mobile 
phase with sodium nitrate added as a to marker. Trace B represents a sample of THP 
racemate chromatographed under the same conditions. The two peaks in chromatogram B 
proved to be of equal area after integration, verifying that the two THP stereoisomers are 
present in equal proportions in the racemate. Chromatogram C depicts an equimolar 
sample of R-(+)-THP and THP racemate. 
Upon integration, the leftmost peak of R-(+)-THP has doubled in area. This 
indicates that the sample of R-(+)-THP and the R-stereoisomer of the racemate coelute in 
a chiral environment. These data, when coupled with the proton NMR spectra, confirm 
the identification of both samples as authentic THP. 
63 
The Effect of ICV Injections ofTHP on Ethanol Consumption in Adult Male Sprague-
Dawley Rats Obtained from the Frederick, MD Harlan Site 
Only data from animals having cannulae tips within the right lateral ventricle or at 
the dorsal rim of the ventricle were included in the statistical analysis. Histological 40 um 
sections were made on a cryostat (Microm HM 505 N) at -30 °C and stained with cresyl 
violet. These sections were visually inspected on a lightfield microscope. A 
representative histological section is shown in Figure 33. 
Figure 33: Representative Coronal Brain Section Showing Typical Cannula 
Placement (Outlined Area Indicates Cannula Tract) 
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The control condition in this experiment consisted of CSF-treated animals, sham-
operated animals, and nai've animals. A one-way ANOVA for independent groups 
revealed no significant differences in alcohol intake between these three control 
conditions, F(2,6) = 2.21 A, p = 0.184. Hence, these data were collapsed into one control 
condition. From this analysis, one can rule out the possibility that the surgical procedure 
itself might affect an animal's preference for (or ability to discriminate between) the 
tastes of alcohol and water. 
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Figure 34: Graph Showing Ethanol Consumption in Response to 20 
nmoles/day ICV Injections of R-(+)-THP and Racemic THP 
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Figure 35: Graph Showing Ethanol Consumption in Response to 40 
nmoles/day ICV Injections of R-(+)-THP and Racemic THP 
The effect of acute ICV injections of (±)-THP or (+)-THP on the preference test is 
shown in Figures 34 and 35. The effects of the lower doses (0.65 and 0.66 (ig/uL) of 
either (±)-THP or (+)-THP on alcohol intake were strikingly different than the effects of 
the higher doses (1.3 and 1.4 (ig/uL) of either compound. As a result, separate mixed-
model ANOVA's were conducted for the lower and higher doses of the alkaloids. For 
the lower doses, the main effect of animals across days was significant, F(l 1,231 )=5.648, 
/K0.001. The main effect of drug treatment was also significant, F(2,21)=9.139, 
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/?<0.001. In addition, the interaction effect (drug treatment over days) was significant, 
F(22, 231)=3.847,/K0.001. 
The effects of lower doses of (±)-THP or (+)-THP are illustrated in Figure 34. 
Post-hoc comparisons revealed a significant increase in consumption of absolute alcohol 
following ICV administration of the lower dose (0.65 ug/uL) of (±)-THP,/?=0.002. 
Compared to controls, the lower dose (0.66 ug/uL) of (+)-THP also significantly 
enhanced alcohol intake, p=0.017. Differences in alcohol consumption between (±)-
THP-treated animals and (+)-THP-treated animals were not significant, ^=0.493. 
The 95% confidence interval test determined that low doses of (±)-THP resulted 
in a significant increase in intake of alcohol from 7%-13% concentrations of ethanol. 
Low doses of (+)-THP significantly enhanced consumption of alcohol from 4%-l 1% 
concentrations and again at 15%-20% concentrations. At no time did drug treatment 
result in a decrease in alcohol consumption relative to control. 
While lower doses of racemic THP induced a preference for alcohol across a mid-
range of ethanol concentrations, the magnitude of the increase was not as pronounced as 
those observed in the initial reports of THP-induced drinking [53, 139]. This may be due 
to differences in dosing regimen. For example, more dramatic increases have been 
observed across a similar range of doses (i.e., 0.1-10.0 |ig/uL), perhaps because the 
dosing regimen was extended throughout the entire 12-day preference test [53, 54, 74, 91, 
95, 101, 140-143]. Although less dramatic, the data reported here indicates that repeated 
central infusion of THP during the test period is not necessary to maintain a change in 
alcohol preference. 
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In contrast to the prominent effects of low doses, ICV administration of the higher 
doses of (±)-THP (1.3 M.g/uL) and (+)-THP (1.4 ug/uL) did not significantly alter alcohol 
consumption (Figure 35). A mixed-model ANOVA revealed that neither the main effect 
of animals across days nor the main effects of drug treatment were significant. 
Additionally, the interaction effect (drug treatment over days) was not significant. 
A summary of the average g/kg ethanol dosage consumed by each experimental 
group appears as Table 5. While these data are not as dramatic as those reported by other 
researchers [53-55, 58, 74, 91, 93, 95, 97, 141, 144-148], they are compelling 
nonetheless. 
Table 5: Average Grams of Ethanol per Kilogram Body Weight Consumed by Each 
Experimental Group Over the Course of the Entire ICV Experiment 
Experimental Group 
+THP (20 nmoles/day) 
+THP (20 nmoles/day) 
Control 
+THP (40 nmoles/day) 
+THP (40 nmoles/day) 
Number of Subjects 
6 
8 
9 
4 
4 
Mean g/kg 
1.83 ±0.25 
1.53 ±0.22 
0.69 ± 0.22 
0.45 ±0.18 
1.02 ±0.18 
A subset of animals from the control condition was subjected to three consecutive 
twelve-day alcohol preference tests due to the fact that previous researchers' report of 
habituation [149]. A one-way ANOVA for repeated measures revealed no significant 
differences in alcohol consumption among these animals, F(2,26)=0A52, p=0.642. 
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Repeated exposure to escalating concentrations of alcohol solutions alone did not alter 
alcohol intake. One can, therefore, rule out habituation or sensitization as possible 
explanations for changes in patterns of alcohol consumption in this experiment. 
In a subset of animals (n=17) treated with either (±)-THP or (+)-THP, alcohol and 
water measurements were taken every four hours around the clock during the twelve-day 
preference test (Figure 36). Most of the intake of both alcohol solutions and water 
occurred during the nocturnal period, with more than a two-fold decline in consumption 
of all fluid occurring immediately thereafter, in the first full four hours of light. Thus, it 
may be assumed that rats do, in fact drink at a specific point in their circadian cycle. 
Lights On 
H20 
EtOH 
Nil 
Lights Off 
X 
X 
I 
10 pm 2 am 6 am 10 am 2 pm 6 pm 
Time of Day 
Figure 36: Bar Graph Showing Fluid Consumption-Distribution For Four Hour 
Periods Across Twelve-Day Ethanol Preference Tests 
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Myers and associates have conducted numerous experiments demonstrating 
volitional alcohol consumption following ICV or site-specific injections of THP, as well 
as other THIQ alkaloids, in rats [150]. However, some investigators have not observed 
any drinking following ICV injections of THP [102]. Even if THP-induced drinking does 
occur, some investigators have expressed doubts concerning the potential relevance of 
these data [99, 151, 152]. Moreover, there are few laboratories that have actually 
confirmed the finding of an increase in alcohol consequent to THP administration [56, 
95, 142]. In the present study, it was found that both (±)-THP and (+)-THP (0.65-0.66 
ug/uL; ICV) induced significant increases in alcohol intake (Figure 34). Most of the 
alcohol was consumed within an eight hour period. 
The lack of effect of the higher doses (1.3-1.4 ug/uL; ICV) of either compound 
was unexpected (Figure 35 or Table 5). Duncan and Deitrich reported enhanced 
consumption of alcohol after ICV administration of THP at doses of 10.4 and 41.6 
nmoles/day [56]. The doses used in the present study are 20 and 40 nmoles of THP per 
day. The principle methodological difference between the two studies concerns the 
dosing regimen. In contrast to the shortened dosing regimen used here, Duncan and 
Deitrich gave injections of 0.02 ug/uL every 15 minutes around the clock, starting two 
days prior to and continuing throughout the preference test [56]. Given the minimal 
dosing regimen used in this study (i.e., two injections/day for three days), one might 
expect a response to the higher of the two doses tested. Alcohol consumption, instead, 
increased in response to the lower dose. 
Other investigators have reported similar findings. Clow et al. [142] found that 
the most marked behavioral response occurred in response to the lower of two doses (0.1 
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ug compared to 1.0 ug) of THP. Even lower doses (50 ng) of THP, delivered 
intraventricularly, have been shown to increase absolute intake of alcohol from 1.0 g/kg 
to 3.5 g/kg/day using the same dosing regimen as the one utilized presently [141]. Site-
specific injections of picomolar concentrations of THP into limbic structures have been 
found to enhance alcohol consumption [93, 94]. Thus, the efficacy of the lower dose of 
either (±)-THP or (+)-THP in the present study was not surprising. Additionally, our 
findings are consistent with prior reports [53, 56, 94, 139] which demonstrate that the 
augmented drinking response does not depend on continuous THP infusion. Enhanced 
drinking continues long after THP clearance. 
Diminishing alcohol consumption at higher doses of THP has been reported 
previously. Indeed, higher doses of THP are capable of attenuating alcohol consumption 
[94]. An inverted U-distribution best describes the dose-response function [150], with 
THP serving as an opiate agonist at lower doses and as an opiate antagonist at higher 
doses [94]. This may explain the lack of response to higher doses of THP tested in the 
present experiment. If relatively few injections of 1.3-1.4 ug/uL of THP are sufficient to 
induce such a ceiling effect [56], then why would a more chronic treatment regimen 
actually enhance alcohol intake? Perhaps a long-term alteration in receptor sensitivity 
occurs. Alternatively, perhaps molecular alterations in signal transduction processes may 
occur in response to chronic treatment with THP. 
While increases in alcohol consumption have been reported previously following 
ICV injection of (±)-THP and (-)-THP [53], this is the first known report of an increase in 
alcohol consumption caused by (+)-THP. The magnitude of the response did not differ 
significantly from the response to racemic THP. In fact, the response was extended to 
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higher concentrations (15% and 20%). These findings are consistent with previous 
reports that (-)-THP induces volitional alcohol intake comparable to (±)-THP [53]. 
Alternative to the hypothesis that morphine is synthesized from the alkaloid, THP 
may act as an opiate agonist. Because of the relative symmetry of the molecule, 
receptors may be unable to distinguish between the two isomers. In either case, one 
might expect both enantiomers would exhibit efficacy equal to the racemic mixture [53]. 
Unfortunately, this data cannot discriminate between these two hypotheses. 
Aldehydes form as a result of the enzymatic degradation of alcohol by alcohol 
dehydrogenase in the liver [31]. These peripherally formed aldehydes may react with 
catecholamines such as dopamine to form THP, as well as other THIQ alkaloids, shown 
to induce ethanol intake. The presumption that THIQ alkaloids are relevant to the 
etiology of alcoholism appears to rest on the assumption that peripherally formed THIQ 
alkaloids can cross the blood-brain barrier, and exert their behavioral effects by binding 
to centrally located receptors. Picomole quantities of THP have been detected in brain 
tissue using high performance liquid chromatography (HPLC) coupled with 
electrochemical detection following peripheral administration of either THP [153] or 
alcohol [154]. 
The highest concentrations of THP were found at axons associated with the 
mesolimbic reward system (e.g., olfactory bulb, frontal cortex, hypothalamus). 
Substantial basic and clinical research findings implicate opioid modulation of this 
dopamine circuit in alcohol addiction [155-157]. Given the structural similarity of THP 
to morphine, the presence of THP in the mesolimbic dopamine system is noteworthy. 
The discriminative stimulus effects of THP and ethanol are apparently dissimilar to those 
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of opiates [158]. Therefore, the biochemical connection is not likely to be direct. 
Nonetheless, once it has crossed over the blood brain barrier, THP was mostly highly 
concentrated in structures [154] that contain both dopamine and opioid receptors. 
The notion that ingested alcohol could conceivably lead to a buildup of THIQ 
levels in the brain has been experimentally tested [159]. Peripherally administered 
ethanol (2 g/kg; IP) resulted in an increase in THP and dopamine levels measured in the 
extracellular space of the nucleus accumbens in alcohol-preferring (AA) and alcohol-
avoiding (ANA) rats. AA rats were generally less sensitive to changes in THP, 
salsolinol, or dopamine than ANA rats. The increases in THP following ethanol 
administration were more pronounced in the ANA rats [159]. 
The fact that peripheral infusion of THP did not influence alcohol consumption in 
this experiment presents a dilemma for the multiple-metabolite theory. One plausible 
hypothesis is that endogenously formed THP does not contribute to any significant 
degree to the etiology of alcohol addiction. In this event, THP and other THIQ alkaloids 
are still pharmacological tools useful for investigating neural mechanisms that regulate 
alcohol ingestion. Since the necessary compounds for endogenous THP production are 
also present in the mammalian brain, it is also possible that centrally formed THP plays a 
role in alcohol consumption. However, the reason for the lack of response to chronic, 
peripheral infusion of THP remains unknown. 
The present experiments confirm previous reports of volitional alcohol 
consumption following central administration of THP. Increases'in alcohol intake were 
observed following administration of the racemic compound, as well as the R(+) - isomer 
of THP, but only at the lower doses tested (0.65-0.66 fig/uL). To our knowledge, the 
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finding that the R(+) - isomer of THP can potentiate alcohol consumption has not been 
reported previously. Increased alcohol consumption in response to low doses of racemic 
THP was observed mostly in the mid-range of concentrations tested (7-13%). The R(+) -
isomer compound induced significant alcohol intake across a mid-range of concentrations 
(4-11%), but also at much higher concentrations (15 and 20%). 
Furthermore, most of the ethanol was consumed within a four hour period each 
day, maximizing the pharmacological effects of ingested ethanol. At present, it is still 
unclear whether or not endogenous THP plays a significant role in the etiology and 
maintenance of alcohol addiction. Nonetheless, the present data verify that central 
administration of THP and its R(+) - isomer can significantly alter drinking behavior in 
rats such that unsweetened alcohol solutions become preferred over water. 
The Effect of ICV Injections of THP on Ethanol Consumption in Adult Male Sprague-
Dawley Rats Obtained from the Prattville, AL Harlan Site 
A population of adult male Sprague-Dawley rats was obtained from the Harlan 
site located in Prattville, AL. These animals were treated in exactly the same manner as 
the experimental animals obtained from the Frederick, MD site in regards to all 
experimental procedures and animal care. This population of rats already, on average, 
drank large amounts of ethanol prior to any ICV injections. 
This was odd, because the conventional animal research wisdom is that Sprague-
Dawley rats are alcohol-aversive. This occurrence of untreated animals drinking 
relatively large amounts of alcohol was heretofore unreported. When contacted about this 
anomalous behavior, representatives from Harlan, Inc. expressed little surprise. They 
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claimed that the outbred strains of laboratory rats that Harlan vends are isolated at each 
individual site. 
Therefore, rats from different plants could be considered, for all intents and 
purposes, to be separate strains with respect to many factors. These factors include heart 
disease, debilitating aging effects, growth curves, respiratory defects, and death rate. The 
representative knew nothing of the potential for alcohol drinking differences, but noted 
that very few labs specify which site they prefer their rats to be shipped from. Of these 
few labs, even fewer conduct addiction-related research, so it was not unusual that Harlan 
had no records of the propensity for these rats from the Prattville site to consume ethanol. 
Only data from animals having cannulae tips within the right lateral ventricle or at 
the dorsal rim of the ventricle were included in the statistical analysis. Histological 40 um 
sections were made on a Microtome cryostat and stained with cresyl violet. These 
sections were visually inspected on a lightfield microscope. Data from this population of 
rats is shown in Figure 37. 
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Figure 37: Bar Graph Depicting Total g/kg Consumption of Prattville, AL Rats 
Across Entire Twelve-Day Ethanol Screening (Rats 5,11, and 1 treated with (+)-
THP; Rats 7, 9,10, and 12 treated with aCSF; Rats 14,15, and 16 treated with THP 
racemate) 
As can be seen from the Figure 37, no THP treatments resulted in elevated 
ethanol consumption. In fact, the only animal to dramatically increase its ethanol 
consumption was Rat 7, a control animal. Control animals, rats 7, 9, 10, and 12, drank 
significantly more ethanol over the course of the experiment than treated animals. While 
rats treated with (+)-THP, rats 1,5, and 11, drank approximately the same amount of 
ethanol as other tested Sprague-Dawley rats from Frederick, MD, THP treatments 
resulted in a decrease in alcohol preference. Rats 14-16 drank elevated levels of ethanol 
before treatment and decreased their drinking with subsequent treatment of THP 
racemate. 
Presently, there is no satisfactory explanation for the behavior observed from 
these Prattville, AL rats. These rats may already have elevated levels of THP present in 
their brain. Raising the endogenous levels of THP through ICV injections may result in 
an aversive dose, as other researchers have observed in previous dose-response curve 
studies of THP [56, 142]. Alternately, the Prattville, AL Harlan plant may have 
unknowingly bred their rats selectively for a high ethanol preference, as Myers and co-
workers have with their HEP rats [97, 160, 161]. 
The Effects of ICV Injections ofTHB on the Ethanol Preference of Adult Male Sprague-
Dawley Rats Obtained from Harlan's Frederick, MD Site 
Only data from animals having cannulae tips within the right lateral ventricle or at 
the dorsal rim of the ventricle were included in the statistical analysis. Histological 40 urn 
sections were made on a Microtome cryostat and stained with cresyl violet. These 
sections were visually inspected on a lightfield microscope. 
These experimental subjects were treated in the exact same manner as previous 
animals with regard to animal care, surgical, injection and cannulae placement 
verification procedures. The only notable difference in the treatment of these animals was 
in the identity of the tested compound. These animals were given ICV injections in the 
amount of 20 nmoles/day of THB. Data from this experimental group appears as Figure 
38. 
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Figure 38: Graph of Control and Experimental Groups of ICV THB-Treated Rats 
As can be seen in the graph, no significant increases are observed when the whole 
population of rats is examined. However, the large standard deviations are the result of 
three subjects' dramatic increases in ethanol consumption. 
As THB is not a precursor to biological opiate alkaloids [162], it is unlikely in the 
extreme that opiate biosynthesis plays any part in these observed results. Also, since 
THB, compared to THP, has a relatively low affinity for opioid receptors [163, 164], it is 
unlikely that this very limited success is due to THB acting as an opioid agonist. Rather, 
it is probably due to the action of THB on dopaminergic receptors, for which it has a 
relatively high affinity [164]. 
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Effects of Ethanol Consumption on Tetrahydropapaveroline Levels in the Cerebrospinal 
Fluid of Adult Male Sprague-Dawley Rats In Vivo 
Microdialysis Recovery Determination 
The amperometric electrochemical detector used in this series of experiments was 
calibrated by injecting various concentrations of THP Hydrobromide in artificial CSF 
(aCSF) onto the Cig ODS column used for future dialysate analyses and plotting the 
detector response as a function of peak area counts. This detector response is given in 
Figure 39. 
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Figure 39: Detector Response of Amperometric Detector to THP 
Hydrobromide 
Flow rates of 0.5, 1.0, and 1.5 (j,L/minute were examined to determine the optimal 
flow rate for an in vivo microdialysis experiment. Since a calibration curve had been 
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established for the detector, determining the percentage of recovered from the dialysis of 
the 0.69 uM "parent" solution was a simple matter of measuring the concentration of the 
dialysate and expressing its concentration as a percentage of the "parent". Results from 
the flow rate experiment are seen as Figure 40. 
Figure 40: Percent Recovery of THP Hydrobromide in Dialysate Solution at Three 
Flow Rates as Measured by HPLC-ECD 
From this flow rate calibration, it can be seen that the optimal flow rate at which 
to operate a CMA/11 microdialysis probe for maximum recovery of THP Hydrobromide 
and repeatability is 1.0 uL/minute. This flow rate was used throughout the in vivo 
microdialysis experiment. 
In Vivo Microdialysis Results 
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Exposure to ethanol prior to collection of dialysate definitely increased 
endogenous THP levels when compared to basal levels. Representative chromatograms 
of analyzed dialysates appear as Figures 41 and 42. The circled peaks in Figures 41 and 
42 have retention times identical to those of prepared THP standards. 
Figure 41: Representative Chromatogram of Dialysate from Rat M2 Before Ethanol 
Exposure 
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Figure 42: Representative Chromatogram of Dialysate from Rat M2 After Ethanol 
Exposure 
The data from the in vivo microdialysis on the three experimental subjects appears 
as Figures 43-46. Amounts of THP in the dialysis solution were calculated using the 
detector response curve displayed as Figure 39. Application of the CMA/11 probe 
recoveries displayed in Figure 40 allows for the estimation of the concentration of THP in 
vivo within the lateral ventricles of the experimental subjects shown in Figures 47-49. 
This experiment was originally intended to be a larger study with seven experimental 
subjects, but three rats damaged their implants prior to final THP level assessment. One 
set of data was lost due to a loss of communication between the electrochemical detector 
and the HP 3 3 96A integrator. 
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Figure 43: Bar Graph showing Elevated Levels of Dialysis THP (Rat Ml) After 
Exposure to Ethanol 
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Figure 44: Bar Graph showing Elevated Levels of Dialysis THP (Rat M2) After 
Exposure to Ethanol 
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Figure 45: Bar Graph showing Elevated Levels of Dialysis THP (Rat M7) After 
Exposure to Ethanol 
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Figure 46: Composite Bar Graph showing Elevated Levels of Dialysis THP of All 
Rats After Exposure to Ethanol 
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Figure 47: Bar Graph showing Calculated In Vivo THP Concentration of the 
Lateral Ventricle (Rat Ml) 
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Figure 48: Bar Graph showing Calculated In Vivo THP Concentration of the 
Lateral Ventricle (Rat M2) 
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Figure 49: Bar Graph showing Calculated In Vivo THP Concentration of the 
Lateral Ventricle (Rat M7) 
General Discussion of the Relevance of Results 
Chiral HPLC columns for the separation of enantiomeric mixtures employing 
chiral stationary phases are quite expensive, have delicate bonded phases, and are well 
documented [116, 128, 165-168]. A desirable alternative to these columns would be a 
cheap and effective method of creating a chiral environment that aids in the separation of 
these stereoisomers. S-[3-CD is just such a compound. It vastly improves resolution of 
catecholamines compared to unsubstituted cyclodextrins [129, 130]. 
While several researchers have conducted studies of cyclized macromolecules or 
ion-pairing agents in HPLC mobile phase additives [115, 117, 129-131, 169,170], no 
published studies have used subambient temperatures to enhance the thermodynamics of 
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separations. The separation of carboxylated salsolinol derivatives using chiral mobile 
phase additives is difficult, at best. However, subambient temperatures coupled with the 
chiral mobile phase additive S-[3-CD allow meager resolution of even these traditionally 
inseparable enantiomers. 
Chiral recognition is an important function for biological systems. Just as only 
one stereoisomer of glucose is important for terran biosystems, only one isomer of 
morphine, the S-isomer, has analgesic effects. Likewise, it was previously thought that 
only one isomer of THP was effective at eliciting an alcohol-drinking response in 
aversive animals. Only the S-isomer was singled out for further study by Myers and co-
workers [58] or Duncan and Deitrich [56]. Sango et al. found only the S-isomer of THP 
to be present in the brains of rats exposed to ethanol [51]. Tabakoff et al. found S-(-)-
THP to be present biological fluids of human alcoholics [171]. The experiment conducted 
with ICV THP injections in Sprague-Dawley rats indicate that R-(+)-THP is just as 
effective at evoking alcohol-addictive responses from rats. 
Whether this result is due to the conversion of R-(+)-THP to the S-isomer or the 
inability of THP-reactive receptors to distinguish between the two is unclear. Also 
unclear is the precise manner in which THP evokes alcohol drinking in aversive rats. 
THP may be converted to morphine in vivo [52, 103, 104, 106, 107, 111, 112, 172-175], 
or THP may act as an opiate agonist and bind with opioid receptors found in the brain 
[146, 163, 164, 176, 177]. It was suggested by one group of researchers that THP may 
have a two-pronged effect, binding with dopaminergic and opioid receptors alike [164], 
depending on the conformational rotamers of THP. 
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THB has very little affinity for opiate receptors, but a much larger affinity for 
dopaminergic neuroreceptors [164]. Hence, it is reasonable to surmise that if THB is 
successful at evoking volitional alcohol consumption in ethanol-aversive rats, 
dopaminergic neurons may be more involved than receptors that are selective for opiates 
in the etiology of alcoholism. However, if THB is unsuccessful at evoking volitional 
alcohol drinking, the converse is most likely true. Since ICV injections of THB were 
successful in inducing alcohol consumption in few experimental animals, it is likely that 
the truth is more complicated than this hypothesis. 
Nonetheless, one fact is undeniable. The gastric gavage of solutions relatively 
high in ethanol concentration did result in a marked increase in endogenously formed 
THP in experimental animals. This fact alone implicates tetrahydroisoquinolines in the 
etiology of alcohol addiction and vindicates the theories of early alcohol addiction 
researchers such as Davis and Walsh [28-31] and Myers [53-55, 58, 96, 139, 178, 179]. 
It is noteworthy that, during the microdialysis experiment, the maximum levels of 
THP were detected within the first three periods of the experiment. THP levels then 
appeared to drop towards basal concentrations. This increase in initial endogenous levels 
of THP following alcohol exposure is startling. While one researcher has assayed THP 
concentration in brain tissues following ethanol exposure [154], no other researcher to 
date has published such a change in THP levels in CSF in "real time" from a freely 
behaving subject [33, 159, 180-189]. While not conclusive by any means, these 
experiments, both the ICV administration of THP and the dialysis of THP from CSF 
following the administration of an ethanol solution, definitely lend credence to the theory 
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that THP and related alkaloids play an important role in the acquisition and maintenance 
of alcohol addiction. 
Observation of the amounts of THP detected in the CSF through microdialysis 
indicate that endogenous THP levels, both basal and elevated through ethanol 
administration, in the lateral ventricle CSF are approximately four orders of magnitude 
less than the demonstrated effective ICV dose of 20 nanomoles of THP per day. This 
finding would appear to support earlier reports that ICV doses as low as 50 ng are 
sufficient to induce elevated ethanol consumption in rats [141]. 
Future experiments expanding on this line of research should replicate these 
experiments with much larger experimental groups from varied rat colonies and facilities. 
Additionally, future experiments should explore the relationship of opiate receptor 
density versus ethanol consumption elicited via ICV injection of THP. Also of interest is 
the relative persistence of endogenously formed THP within the CSF of subject Ml. 
Whether this is a function of relatively low metabolic rate of the disposition of THP 
within this particular subject is, as yet, unclear. Future researchers should also focus on 
the determination of individual neurochemical and neuroanatomical variations as 
contributing factors to the etiology of alcohol addiction. 
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Application for Use of Animal Subjects 
Principal Investigator's Name (Please Print): 
John G. McCoy 
Office Phone Number: «H-2«M6I7 
Department: 
Psychology 
Mail Box: 5025 
Signature Approvals 
H-l-ol 
Pririefpal Investigator 
jartment Cnair J 
Date 
Dep  
£& 
Date 
D/te / lACUUCha 
IACUC Official Approval 
MJU- 0D > 
Protocol # 
V^Ar 
Expiration Date 
Renewal # Expiration Date 
Renewal # Expiration Date 
I, FUNDING INFORMATION 
Is this application associated with a grant? 0Yes QMo 
If yes, list the title used on the grant application to assure proper notification of the 
approval to the funding agency. 
If no and you do not require verification of approval for an outside funding source, you 
may list the fund source as "departmental." The duration dates for departmentally funded 
projects must not exceed three years. 
Funding Agency or Fund Source: 
NIH: Academic Research and Enhancement Award (AREA); and NIB (Center for Psychiatric Neuroscience Small Grant) 
Grant or Project Title: 
Modeling Alcohol Addiction: Role of Mammalian Alkaloids 
Grant or Project Duration (beginning and ending dates): 6/1/03 - 6/1/06 
This application is (check one) 
0New 
•Addendum/Modification 
•Renewal (required every three years and must be reviewed by IACUC to ensure that all 
current federal guidelines are being met) 
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II. ASSURANCE STATEMENTS 
PRINCIPAL INVESTIGATOR 
I certify that I have truthfully and completely described the use of animals for this project/grant 
and that I will notify the Institutional Animal Care and Research Advisory Committee in writing 
of any changes in this information prior to proceeding with the animal use. Furthermore, the 
activities I plan do not unnecessarily duplicate previous experiments. 
As a Principal Investigator, I accept and will conform to all federal, state, and institutional laws 
or guidelines concerning: care and use of animals in research, teaching, or testing; efforts to 
minimize animal pain and distress; training of any research personnel or students handling 
animals as described herein; and consideration of alternatives to animal use in research. 
1 ^ 4-7-aj 
Principal Investigator's Signature Date 
CO-INVESTIGATOR 
I understand that my name is listed on this project as a co-investigator. I have read this 
application and understand that only the described procedures are to be conducted. 
Name (typed) Signature 
J Ken D. McMurtrey; Ph.D. V0l*JftLAs&i i[/o)03 
RESEARCH ASSOCIATE 
I understand that my name is listed on this project as a research associate (this would include all 
graduate and/or undergraduate students involved in this project). I have read this application and 
understand that only the described procedures are to be conducted. 
Name (typed) Signature / / , . 
1 J- ChTis Strawbridge Ljf^ ^ MAA*J%S4^ VlP/oS 
DEPARTMENT CHAIR APPROVAL 
I understand that responsibility for assessing the quality of animal research must be shared by 
both the department and the IACUC. My signature as Department Chair certifies that the 
proposed research has been reviewed and approved as having scientific merit. 
^Hr^n ^ ~ci 
loTDepsfrt: Signature 6t epartment Chair Date 
III. NONTECHNICAL (LAY) SUMMARY OF PROJECT 
The lay summary should be written in non-scientific terms that can easily be understood by a 
layperson and should include the following: 
* a description of the potential benefits of the project 
* an overview of the goals of the project 
* a statement that mentions all of the species to be used and their importance to the project 
Please limit your description to the space provided in the box below. 
Ingested ethanol is metabolized, to a large extent, by liver alcohol dehydrogenase to acetaldehyde, which can condense with 
dopamine to form salsolinol (SAL). Alternatively, dopaldehyde can condense with dopamine to form tetrahydropapaveroline 
(THP). another isoquinoline alkaloids. Patients with alcoholic parents had lowered (R)-SAL and (S)-SAL levels compared 
with family history negative alcoholics, suggesting genetic association of disturbance of SAL biosynthesis and alcoholism. In 
rats, intraventrentricular injections of SAL or THP have been shown to induce long-lasting preferences for alcohol solutions 
over water. However, the critical issue is not whether TIQ's can have behavioral effects, but whether endogenously formed 
TlQ's are produced in sufficient amounts to exert a significant influence on volitional alcohol consumption. Only one 
published report has attempted to address this issue. These results were consistent with the hypothesis that alcohol infusion 
can influence central formation of TIQ's. 
The proposed experiments will evaluate levels of SAL or THP from the shell and core of the nucleus accumbens using in vivo 
microdialysis following oral infusion of ethanol (1.0, 1.5, 2.0 or 2.5 g ethanol/kg), delivered by gavage in a 5 mL volume. 
Sprague-Dawley rats will be used. To evaluate whether voluntary versus involuntary oral administration of ethanol influences 
extracellular SAL levels differentially, separate experiments will employ the 12-day "step-up" procedure in which animals are 
free to select an escalating concentration of ethanol or water. Briefly, three graduated 100 mL drinking tubes, were placed in 
front of each animal's cage. One tube contained deionized water. A second tube was empty, and a third contained an alcohol 
solution in water that increased in ethanol concentration over the course of the 12 days. The concentration of ethanol 
(Everclear) was increased each day in the following manner: 2, 3, 4, 5, 7, 9, 11, 13, 15, 20, 25, and 30% ethanol by volume. 
Prior experiments in our laboratory and others have confirmed that most Sprague-Dawley rats avoid even low concentrations 
of ethanol in this paradigm. However, a smaller percentage of animals will voluntarily select even high concentrations of 
unsweetened ethanol (15-20%) over water. These alcohol-preferring animals can be used to evaluate the effects of voluntary 
ethanol consumption on SAL levels in the nucleus accumbens. The proposed experiments will shed light on the unresolved 
and controversial issue of whether endogenously formed T1Q alkaloids may be involved in the etiology and/or maintenance of 
an addiction to alcohol. 
IV. JUSTIFICATION FOR USE OF ANIMALS 
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Type of animal (one per form) 
Amphibians Birds Fish Mice 
Rabbits Reptiles * Rats 
Other (please specify) 
Sex </ Male Female Either or mixed 
Strain/sDecieS Sprague-Dawley rats (Harlan, Indainapolis, IN) 
Size or Age 60 days of age 
1. Why must you use animals in the proposed studies? 
The proposed set of experiments examine the hypothesis that endogenous THP formation in the brain may be a 
critical factor in the etiology of alcohol addiction. To answer this question directiy, a microdiaylsis tube is inserted 
through a surgically implanted chronic, indwelling metal cannula. For obvious reasons, it is impossible to conduct 
this experimental procedure in humans. An in vivo model is necessary to ascertain whether or not THP formation 
occurs in the brain in sufficient quantities to influence further drinking behavior of the animal. The findings will be 
important from both a theoretical and clinical point of view. From the a clinical viewpoint, it would provide a 
potential target for development of new pharmacological approaches to treat alcoholism. 
Was a literature search performed to ensure that there is no duplication with the work that 
is being proposed? ^ Yes No 
If yes, then please provide details about the method used for the literature search (i.e. 
database used) including when the search was performed and what keywords were used. 
An Internet search using Pubmed was conducted in March 2003. The following keywords were used: 
tetrydropapaveroline, salsolinol, microdialsysis, isoquinoline alkaloids. 
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V. NUMBER OF ANIMALS TO BE USED PER YEAR 
Please explain how you determined the number of animals needed to accomplish the proposed research. 
For experiments in which there will be statistical analysis of data collected from the animals, please 
briefly describe the type of analysis that will be performed and how that effected the number of animals 
to be used per group (or per time point) for each experiment or each series of similar experiments. 
Levels of THP will be assessed via microdiaiysis following either involuntary oral administration of ethanol or voluntary consumption 
of ethanol. The experimental procedure for involuntary oral administration of ethanol is as follows. Levels of THP will be assessed 
following oral administration of 1.0, 1.5, 2.0 or 2.5 g ethanol/kg, delivered by gavage in a 5 mL volume. Control animals will receive 
an equal volume of water by gavage. Power analyses were conducted utilizing GPOWER(Faul &Erdfefder, 1992) to determine the 
sample size for this experiment. Based on the power observed in previous experiment (Sallstrom et ah, 1999), a strong effect size is 
expected. Current anlysis revealed that a total sample size of N = 55 ( n = 11 per group) should be sufficient to observe significant 
differences between groups and achieve an anticipated power greater than 0.80. 
Another N = 55 ( n = 11 per group ) animals will be used to evaluate Salsolinol following oral administration of 1.0, 1.5,2.0 or 2.5 g 
ethanol/kg, delivered by gavage in a 5 mL volume or an equal volume of the vehicle. The rationale for the number of animals is the 
same as for the THP experiments (above). 
Write the number of animals to be used per procedure category for each year of the project in the table 
below; (If you write in the number of animals for one year only, the Committee will assume that 
number is adequate for the full duration of the project.) If an animal will be used for procedures of 
varying categories, write the number only in the category for the maximum level of pain/distress that the 
animal may experience. Please see the instruction sheet for examples of experimental use of animals 
and the category applicable for that research. 
Category 
1 
2a 
2b 
2c 
3 
Description of Procedure Category 
Procedure will produce minimal, transient, or no 
pain/distress (e.g. minor injections or collections) 
Nonsurgical procedures will be performed using 
anesthetics, analgesics or tranqulizers to alleviate 
possible pain/distress. 
Nonsurvival surgical procedure will be performed 
using anesthetics, analgesics or tranquilizers to 
alleviate possible pain/distress. 
Survival surgical procedures will be performed 
using anesthetics, analgesics or tranquilizers to 
alleviate possible pain/distress. 
Procedures mav produce pain/distress which will not 
be relived by anesthetics, analgesics, or tranquilizers, 
Numbers of Animals 
per Year 
1 
37 
2 
37 
3 
36 
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VI. EXPERIMENTAL PROCEDURES 
In this section a technical description of the use of the animals in the proposed research to be conducted should 
be given. This section can be either written in a narrative description or drawn as a flow diagram (examples are 
given in the instructions that accompany this form). Either choice should include all technical details necessary 
for the committee to fully understand the use of the animals in the proposed research. The type of information 
that should be included is the number of animals to be used per procedure, the treatment and control groups, 
duration of the proposed research, care of the animals during the proposed research, and what will be done with 
the animals at the end of the research. Conciseness will be appreciated, but you may use additional pages if 
necessary. 
Although rats are known to be relatively resistant to infections, subacute infections resulting in behavioral and physiological changes have been 
demonstrated (Bradfield et a!., 1992). The risk of postoperative infection will be minimized by adhering to aseptic surgical practices 
(Cunliff-Beamer, 1993/4). Our facility and procedures have been reviewed by Tom Ricks, D.V.M. (see below). We have a lab area dedicated to 
stereotaxic surgical procedures which is equipped with mounted surgical lighting. An industrial steam pressure cleaner is used to wash animal 
cages / racks. Glassware is cleaned with Alconox / Liquiox. Quatricide PV brand germicide is also used for cage cleaning. Instruments, gauze 
pads, and cotton tip swabs will be initially sterilized in an autoclave (121 °C for 15 min) in Johnson Science Tower. When multiple surgeries are 
performed per day, instruments are washed with disinfectant and re-sterilized with a portable Hot Bead Sterilizer. Sterile surgical drapes may be 
used to cover the animal and also help to prevent hypothermia. A 60-W desk lamp will also be used to warm the animal while it is anesthetized. 
Lab coats and sterile gloves are worn by the surgeon. The immediate surgical area is sterilized using 70% ethyl alcohol. During surgery, 
instruments will be maintained in a solution of Zephiran chloride. 
Surgical Procedures: For microdialysis experiments, animals will be anesthetized with ketamine/xylazine anesthesia (25:5 mg/kg body weight; 
IM). Atropine (0.3 ml of a 0.54 mg/ml) solution may also be administered if excessive secretions of the mouth and lung are present. Also, a 
2-ounce rubber squeeze ball and tube will be used to aspirate mucous from the back of the tongue if breathing becomes labored. The animals head 
from behind the tips of the ears to the eyes and across the skull will be shaved with an electric razor prior to the incision. Chlorhexiderm Surgical 
Scrub will be used to clean the incision site. The incision will be about 2.5 cm in length and will be performed using sterile #10 scalpel. 
Following the initial incision, the periosteum is scraped to either side of the skull and the membrane is then clipped with bulldog clamps. After 
cleaning and drying of the skull with cotton swabs and saline, a pencil point is made at the designated coordinates. Both bregma and lambda 
reference points are used to verify the appropriate site for drilling. Following the implant of the cannula for microdialysis probe, the entire area is 
cleaned with Betadine or Chlorhexiderm. Dissolved silk suture (3.0) is used to sew the fascia and skin together around the area of the pedestal 
holding the cannula or probe. 
The implementation of the guide cannula and the microdialysis probe into the nucleus accumbens will follow procedures for which there is an 
established precedent (Sallstrom et al., 1999). Under ketamine / xylazine anesthesia, a guide cannula will be implanted. Using the bregma 
reference point, stereotaxic coordinates will be anterior 1.7 mm, lateral 1.3 and ventral -6.5 mm (Paxinos and Watson, 1986). The rats will be 
placed individually in a macrolon cage (size 34 X 30 X 25 cm) and tethered to the swivel in a noise-insulated room with two cages present. After 
three days, a CMA 10 probe (2 mm dialysis membrane) will be inserted and perfused with artificial cerebrospinal fluid (aCSF: 137 mM Na+, 1.2 
mM Ca2+, 2,4 mM K+, 144.2 mM CI -, 1.2 mM Mg 2+, 0.9 mM NaH2P04.H2O and 1A mM Na2HP04.2H20; pH 7.0) at a flow rate 1.0 *i/min, 
with sampling at intervals of 20 minutes for up to 200 minutes following oral gavage administration. There will be a 24 hour delay before 
collection of dialysate begins in order to minimize stress associated with implantation of the intracerebral dialysis probe. The first 5 samples 
determine basal levels of THP or salsolinol from CSF prior to ethanol administration. 
Experimental Procedure: Levels of THP or salsolinol wiil be assessed following oral administration of ethanol. Levels of THP will be assessed 
following oral administration of 1.0, 1.5, 2.0 or 2.5 g ethanol/kg, delivered by gavage in a 5 mL volume. A 5 mL oral infusion of 20% ethanol by 
gavage would equate to a 2.63 g/kg dose for a typical 300 g rat. This amount has been shown to induce clear signs of intoxication (Cowen, Chen, 
Jarrott & Lawrence, 1998). Animals in the control group wiil receive oral infusion of an equal volume of water. Our dose range of ethanol is 
comparable to those evaluated by other investigators (Lucas & McMillan, 2002; Fadda, Mosca, Columba & Gessa, 1989). 
Perfusion for Histology: After completion of the experiment, the position of the probe will be evaluated by fixing the brain in a formalin solution 
by cardiac perfusion. Animals will be deeply anesthetized with an IP injection of 60 mg/kg sodium pentobarbital. A lack of response to a paw 
pinch is necessary before the perfusion procedure begins. With the rat laying on its back, the paws are pinned to a dissecting tray at an angle so 
that the runoff of blood, saline, or fixative can be collected in the basin. Large scissors are used to cut through the abdominal wall (with the scissor 
tips pointed upward to avoid cutting organs. The incision is made about halfway between the animal's pelvic region and ribcage. A cut is made 
anteriorly until the sternum is reached and then cut laterally along either border of the ribs. The body wall is then pinned back so that the 
diaphragm is exposed. A cut is made along the border between the diaphragm and the ribs, exposing the heart and lungs. A cut is made on either 
side of the ribs as laterally as possible, forming a flap that can be lifted up. A hemostat is attached to the sternum, the ribs are lifted anteriorly, and 
the heart is exposed. The pericardium around the heart may be removed with a pair of blunt forceps, A cannula is inserted into a small incision in 
the left ventricle and another incision is made in the right atrium with fine-tip forcep to drain blood (exsanguination). When the fluid leaving the 
heart is clear (using about 150 ml of saline), the valve to the saline is shut off and the valve from the formalin container is opened up and 300-400 
ml of formaline is slowly infused into the animal. 
Bleeding Procedure: Blood alcohol level will be tested in a subset of animals treated with ethanol. Blood will be drawn by tail snip procedure in 
which an incision is made on the last 1 mm of tissue. Blood is drawn into heparinized capillary tubes and transferred into aliquots for storage at 
-80 degree F freezer. 
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VII. ANIMAL DISPOSITION 
Based on the "Report of the AVMA Panel on Euthanasia 2000" the following methods of euthanasia are 
considered either acceptable or conditionally acceptable. Place a checkmark next to the procedure(s) that will 
be used to euthanize any animals for this project. The animals will be euthanized by the attending veterinarian, 
the animal facility supervisor, a laboratory animal technician, or a researcher who has received special 
permission from the attending veterinarian and the IACUC. If the researcher is desiring special permission to 
perform the euthanasia please indicate in the appropriate space below. You must provide scientific justification 
(including a detailed literature search) in order to obtain approval for a method not listed below. If the species 
you are working with is not listed below, please consult with the attending veterinarian for an acceptable 
method prior to submission of this form. 
Species 
Amphibians 
Birds 
Fish 
Rabbits 
Reptiles 
Rodents 
Acceptable Method 
Barbiturates 
Inhalant anesthetics 
C0 2 
Double pithing 
IMS 
MS 222 
Benzocaine hydrochloride 
Barbiturates 
Inhalant anesthetics 
C0 2 
Barbiturates 
2-phenoxyethanol 
co2 
TMS 
MS 222 
Benzocaine hydrochloride 
Barbiturates 
Inhalant anesthetics 
C0 2 
Barbiturates 
Inhalant anesthetics 
co2 
f Barbiturates 
Inhalant anesthetics 
• CO, 
Conditionally Acceptable Meth 
Decapitation and pithing 
Stunning and decapitation 
Cervical dislocation 
Decapitation 
Decapitation and pithing 
Stunning and 
decapitation/pithing 
Decapitation and pithing 
Stunning and decapitation 
Decapitation 
Cervical dislocation 
(in mice and rats (< 200 g)) 
VII. ANIMAL DISPOSITION fCONT.) 
Species not listed above will need to be specified here along with the method of euthanasia to be 
employed and the signature of the attending veterinarian acknowledging that this method is acceptable. 
Signature of attending veterinarian Date 
Does the researcher desire permission to perform the euthanasia? "' Yes No 
If yes, then please specify why you wish to perform the euthanasia yourself. 
To ensure that the microdialysis probes are localized within the nucleus accumbens, histological sectioning and staining of brain tissue 
is necessary. Cryosectioning, in turn, requires that the brain tissue be fixed using formalin solution. Thus, intracardial perfusions are 
necessary for these experiments. 
Will you have tissues that may be made available to other investigators with approved, active protocols? 
Please note that the other investigator can have an approved, active protocol with either our institution 
or another institution. If the other investigator is at another institution a copy of their approved, active 
protocol will be necessary to have on file before the tissues can be released. Yes ^ No 
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VIII. FACILITIES FOR ANIMAL USE 
Where will the animals be housed? 
Johnson Science Tower animal facility 
(rabbits must be maintained in this facility, as well as all animals involved in biohazardous 
research that aren't being conducted at the Toxicology laboratory at GCRL or animals involved 
in surgical procedures) 
"* Owings-McQuagge animal facility 
(only rodents may be maintained in this facility) 
Wet lab in Walker Science Building 
(only fish, reptiles, and amphibians may be maintained in this facility) 
Toxicology laboratory at GCRL 
Wet lab facilities at GCRL 
Field (requires information to be provided in Appendix H) 
other (specify) 
Describe any special housing requirements that may be needed, especially if the animal will be exposed 
to hazardous materials. 
Will animals be maintained outside the above stated facility overnight for periods longer than twelve 
hours? Yes *' No 
If yes, provide the following information: 
a. Proposed location(s) where animals will be housed?_ 
b. Estimated number of animals or cages to be housed at any given times? 
Length of time animals will be.housed? 
d. Reason(s) why animals must be housed outside designated animal facilities? (Note: convenience 
is not adequate justification for housing outside of approved animal facilities) 
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IX. ANIMAL MEDICAL EMERGENCIES 
In the table below, list the names of individuals who have authority to approve animal treatment or euthanasia. 
If the designated individual(s) cannot be reached, then the Animal Research Facility veterinarian will provide 
supportive care or euthanatize animals suffering unrelenting pain. 
Name 
John G. McCoy 
Julie Rich 
Work Phone Number 
266-4617 
266-5617 
Emergency Phone Number 
266-5197 
297-8936 
X. REQUIRED APPENDICES 
(This page MUST be submitted with the application) 
A. ANTIBODY PRODUCTION 
Will animals be used for antibody production? 
If yes, then complete and attach Appendix A. 
B. NONSURGICAL PROCEDURES NOT INCLUDING ANTIBODY 
PRODUCTION 
Will animals be subjected to nonsurgical procedures (i.e. injections (not including those 
routinely used to administer euthanasia agents), radiographs, oral treatments, etc.? 
If yes, then complete and attach Appendix B. 
C. BREEDING COLONIES 
Will pregnant animals be required or will a breeding colony be established specifically 
for this project? 
If yes, then complete and attach Appendix C. 
D. SURGICAL PROCEDURES 
Will animals be subjected to nonsurvival and/or survival surgical procedures? 
If yes, then complete and attach Appendix D. 
E. PROLONGED PHYSICAL RESTRAINT OF UNANESTHETIZED ANIMALS 
Will unanesthetized animals be subjected to physical restraint for periods of longer than 
one hour? 
If yes, then complete and attach Appendix E. & 
F. PROCEDURES INVOLVING PAIN/DISTRESS WITHOUT PAIN/DISTRESS 
MEDICATION 
Will animals be subjected to procedures that may produce pain/distress which will not be 
relieved by anaesthetics, analgesics, or tranquilizers? 
If yes, then complete and attach Appendix F. 
G. USE OF GENETICALLY MANIPULATED ANIMALS 
Will genetically manipulated animals be used? 
If yes, then complete and attach Appendix G. 
H. WILD ANIMAL AND/OR FIELD RESEARCH 
Will wild animals be used in this research and/or will wild animals be held in the field 
while research is being conducted on them? 
If yes, then complete and attach Appendix H. 
I. SAFETY 
Will living animals be exposed to any of the following: recombinant DNA, infectious 
agents, toxic chemicals, flammable or explosive materials, and/or carcinogens? 
If yes, then complete and attach Appendix I. 
Yes? • 
• 
• 
No? • 
• 
• 
• 
• 
• 
* 
• 
NONSURGICAL PROCEDURES NOT INCLUDING ANTIBODY PRODUCTION 
Place a check by the procedures that will be used in this application. 
0Oral treatments 
DTopicai applications 
•Radiographs 
I lExercise studies 
•Environmental 02 variations 
•Blood pressure monitoring 
[EJnjections (IV, SQ, IM, etc.) 
•Non-surgical catheter use 
•intranasal administrations 
•Abnormal noise levels 
•Abnormal light levels or cycles 
•Food or fluid restrictions 
•Exposure to abnormal temperature dOther (describe) 
0Blood collections 
•Fluid collections 
•Behavioral studies 
•E.K.G. 
•Ocular exams 
•irradiation 
Will the use of paralytics be required for these procedures? 
•Yes BNo 
(Paralyzing drugs must be used only while the animals are fully anesthetized/sedated. If paralytics will 
be used, blood pressure and heart rate must be monitored. Describe the methods that will, be used to 
monitor for possible elevations in blood pressure and heart rate to ensure that adequate levels of 
anesthesia/sedation are maintained while the animals are paralyzed). 
Will the use of anesthetics be required for these procedures? 0Yes IZ]No 
List the anesthetic agent(s) that will be used. 
Agent 
ketamine/xylazine anesthesia 
Dose (mg/kg body wt) 
25:5 mg/kg body weight 
Route 
IM 
Frequency 
Once prior to surgery 
fOcJ^ 
of the appropriate animal facility supervisor and/or attending veterinarian 
Briefly describe the technique to be used for the procedure(s). Include in your description the frequency 
and the maximum number of procedures to be conducted per animal. 
An intramuscular injection of ketamine / xylazine anesthesia (25:5 mg/kg BW) will be given prior stereotaxic surgery (one cannula 
implant per animal). This anesthetic takes full effect within about 20 minutes. The surgical stage of anesthesia is characterized by 
reduced muscle tone, no spontaneous movement, no reaction to painful stimuli (paw or tail pinch) and lack of eyeblink when eyelid is 
touched. Respiration should be regular. Because ketamine prevents the eyelids from closing, an eye lubricant (Paralube Vet ointment) 
is applied. 
SURGICAL P R O C E D U R E S 
An investigator planning on performing surgical procedures must submit documented proof of formal training 
with this application. The training must have occurred within the last five years. Even with documentation it 
will still be necessary for all initial surgical procedures to be performed under the supervision of the attending 
veterinarian or an approved substitute. The following questions should be filled out with the assistance of the 
animal facility supervisor and/or the attending veterinarian. Questions 4 through 6 and 11 require the signature 
of the animal facility supervisor and/or the attending veterinarian prior to submission of this application. 
1. Will nonsurvival surgical procedures be conducted for this application? 
•Yes 0No 
2. Will survival surgical procedures be conducted for this application? If animals will recover from 
anesthesia for any time following surgery, it must be considered as a survival procedure. 
0Yes DNo 
3. Which of the following parameters will be used to determine the pre-operative health status? 
•Activity level | [Heart rate 
•General physical condition plRespiratory rate 
•Body temperature 0Body weight 
•Blood chemistries Dither (specify) 
4. Please specify when, prior to surgery, food and fluids will be withheld. 
Food will be withheld the evening prior to surgery. Water will be available ad lib. 
5. Will pre-operative, medications (i.e. antibiotics, anticholinergics, tranquilizers, etc.) be used? 
•Yes (list them below) 0No 
Medication Dose (mg/kg body wt) Route Frequency 
ICJ^ 
of the appropriate animal facility supervisor and/or attending veterinarian 
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6. List the anesthetic agent(s) that will be used. 
Agent 
ketamine/xylazine anesthesia 
Dose (mg/kg body wt) 
25:5 mg/kg body weight 
Route 
IM 
Frequency 
one or two (40% supplemental) 
Signature of the appropriate animal facility supervisor and/or attending veterinarian 
7. Will paralytic agents be used? [UYes (list them below) 0No 
(Paralyzing drugs must be used only while the animals are fully anesthetized/sedated. If paralytics will 
be used, blood pressure and heart rate must be monitored. Describe the methods that will be used to 
monitor for possible elevations in blood pressure and heart rate to ensure that adequate levels of 
anesthesia/sedation are maintained while the animals are paralyzed). 
Agent Dose (mg/kg body wt) Route Frequency 
Signature of the appropriate animal facility supervisor and/or attending veterinarian 
8. For each surgical procedure that is to be conducted, address the following: 
a. List the site(s) that will be used for the incision(s). 
The incision will be about 2.5 cm in length along the midline of the scalp from a point between the ears and proceeding anteriorly. 
b. Describe how the surgical site(s) will be prepared. 
The animals head from behind the tips of the ears to the eyes and across the skull will be shaved with an electric razor prior to the 
incision. Chlorhexiderm Surgical Scrub will be used to clean the incision site. The incision will be performed using a sterile #10 scalpel. 
Following the initial incision, the periosteum is scraped to either side of the skull and the membrane is then clipped with bulldog clamps. 
c. Fpr all survival procedures, describe the type(s) of closure materials that will be used (i.e. clips, 
types of suture materials, etc.). 
3.0 Surgical silk suture material is used. 
d. For survival procedures conducted on non-rodent mammals, list the basic suture patterns to be 
used (i.e. continuous, simple interrupted, mattress, etc.) for underlying tissues and skin. 
A simple interrupted suture pattern will be used. Usually one or two sutures anterior to the cement pedestal and one or two sutures 
posterior to the pedestal are sufficient. 
e. Provide a brief description of the nonsurvival and/or survival surgical procedures. 
After cleaning and drying of the skull with cotton swabs and saline, a small hole is drilled in the calvarium where the guide cannula is to 
be lowered. Three additional half-holes are drilled in a triangular region around the cannula hole. Anchor screws are inserted to a depth 
of 1 mm to provide support for the cannula pedestal. The surface of the skull is cleaned with saline and cotten swabs. A think paste of 
dental acrylic (methacrylate and powder) is prepared in a watchglass. A think metal spatula is used to apply the dental acrylic to the skull 
and anchor screws. Successive layers of acrylic are applied until the anchor screw heads are completely covered. Following the implant 
of the guide cannula, the entire area is cleaned with Betadine or Chlorhexiderm. Silk suture (3.0) is used to sew the fascia and skin 
together around the area of the pedestal holding the cannula or probe. Following surgery, animals are placed on a warming pad. 
f. If nonsurvival procedures (animals will not be allowed to regain consciousness) will be 
conducted, explain how long the animals will be maintained under anesthesia prior to euthanasia. 
9. Will any animal be subjected to multiple, major survival surgical procedures? [jYes 0No 
If yes, answer questions a-c below. 
a. Are the surgeries related components of the project? Explain how they are related and why they 
are a scientific necessity. 
b. How many surgeries in addition to the primary surgery will be conducted per animal? 
c. How long will animals be allowed to recover between surgeries? 
10. During anesthesia what methods or parameters will be used to monitor the animal? 
To prevent hypothermia, an insulated pad will be placed beneath the animal and a heating pad will be used post-surgery. Normal rectal 
temperature should be 37.5 degrees C. Labored breathing in an anesthetized animal be produced by excess mucous that needs to be 
cleared from the mouth. Placing the animal on a 35 degree incline (nose down) will allow fluids to drain from the respiratory tract. A 2 
ounce rubber squeeze ball and rube may be used to clar mucous from the mouth. Gasping and wheezing indicates the need for aspiration. 
Aspiration is accomplished by inserting a rubber tube connected to a 5 cc syringe about 3 cm into the throat. Repeated aspiration, 
however, should be avoided since it only produces more mucous. A rat that feels no pain breaths deeply and regularly throughout the 
surgery. Shallow or irregular breathing may indicate either that the animal is too lightly anesthetized or conversely, it may indicate an 
anesthetic overdose. Pedal and corneal reflexes will be tested throughout surgery to assess level of anesthesia. Twitching and leg 
movement also identify an animal that is too lightly anesthetized. A supplemental (40% of initial injection volume) dose may be 
administered. If an animal is overanesthetized, the surgery should be stopped and breathing may be assisted rubber tube. 
11. Animals that will be allowed to regain consciousness following surgery must be closely monitored until 
they regain the ability to control their head movement and maintain sternal recumbency. From the list 
below, check the parameters that you will use to monitor the animals' recovery from anesthesia. 
Ejfeody Temperature Qfeart Rate 0Respiratory Rate 
DPalpebral Reflex DSwallow Reflex ElResponse to External Stimuli 
EJvIuscle Control QMucous Membrane Re-fill Times D31ood Pressure 
•Other (specify) 
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12. The postoperative period is considered at an end when the skin sutures are removed or the wound is 
healed. 
a. How frequently will animals be monitored during this period? 
Body weight, water consumption and appearance will be monitored daily. Fluids (1-cc of saline) may be given SC. 
b. Describe any anticipated, clinically significant, adverse effects that may result from the surgical 
manipulation and the care that will be provided should they occur. 
Signs of postsurgical distress include a hunched back, failure to groom, reduced body weight and food intake, and extreme 
vocalization in response to handling. If any of these signs are observed, Dr. Ricks will be consulted. The analgesic listed 
below has been recommended due to its relatively long duration of action (8-12 hours). 
c. From the list below, check the parameters that will be used to determine the presence of 
postoperative pain/distress. 
0Body Weight 0Appearance tZJResponse to External Stimuli 
0Respiratory Rate [ZlHeart Rate 0Unprovoked behavior 
• B o d y Temperature 0Body Posture ClOther Clinical Signs (explain) 
13. Will postoperative antibiotics and/or analgesics be given? 
0Yes (list them below) Oslo 
Medication 
Buprenorphine 
Dose (mg/kg body wt) 
0.02-0.05 mg/kg 
Route 
SC 
Frequency 
As prescribed by veterinarian 
Signature of the appropriate animal facility supervisor and/or attending veterinarian 
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